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ABSTRACT 
Bacterial pneumonia (BP) is an acquired inflammation of the lower airways 
and lung parenchyma secondary to bacterial infection. BP is difficult to induce 
experimentally in healthy dogs; the pathogenesis is therefore considered 
complex, involving several underlying mechanisms. BP was first described in 
dogs decades ago, but it is still one of the most common systemic bacterial 
infections in dogs, with a significant morbidity and mortality. Several aspects 
of BP, including the applicability of inflammatory biomarkers in its diagnosis 
and follow-up as well as the role of respiratory viruses in its clinical picture 
and development, warrant further studies.  
This thesis aimed to describe clinical findings during the disease and 
recovery periods in dogs with BP and to evaluate the applicability of acute-
phase proteins as diagnostic and follow-up markers in BP. The prevalence and 
role of viral co-infections in dogs with BP were also investigated. 
We evaluated the diagnostic applicability of serum C-reactive protein 
(CRP) and noted that CRP is significantly elevated in BP relative to dogs with 
other lower respiratory tract diseases, such as chronic bronchitis, bacterial 
tracheobronchitis, canine idiopathic pulmonary fibrosis, and eosinophilic 
bronchopneumopathy, as well as cardiogenic pulmonary edema. Our results 
indicate that serum CRP concentration may be used as an additional 
biomarker in the diagnosis of canine BP.  
Serum CRP, serum amyloid A (SAA), and haptoglobin (Hp) were followed 
during the disease and recovery periods. The follow-up study showed that 
serum CRP and SAA reflected well the recovery process and declined rapidly 
after initiation of successful therapy and could therefore be used as markers of 
treatment response in dogs with BP.  
Currently, markedly longer antibiotic courses are recommended in dogs 
with BP than in humans with pneumonia. Since serum CRP is a sensitive 
inflammatory biomarker, it was hypothesized that normalization of serum 
CRP could be used as an indicator for the cessation of antimicrobial therapy. 
In our study, we treated a group of dogs according to conventional 
recommendations. In another group, antimicrobial therapy was ended 5-7 
days after CRP normalization. When the normalization of CRP was used to 
guide antimicrobial therapy, treatment length was significantly reduced 
without increasing the number of relapses. According to these results, 
normalization of serum CRP may be applied to guide the length of 
antimicrobial therapy in dogs with BP. 
Respiratory viruses, primarily canine parainfluenza virus, were found 
frequently in lower respiratory tract samples in dogs with BP. This indicates 
that viruses may play an important role in the etiology and pathogenesis of BP. 
Viral co-infections did not affect disease severity or clinical variables. 
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Our findings add new knowledge about the natural course of BP as well as 
about the possible applications of acute phase protein measurements in the 
diagnosis and follow-up of BP. The utilization of acute phase protein 
measurements may allow a more precise diagnosis of BP, enable the early 
identification of patients with a poor response to treatment, and diminish the 
use of antimicrobial drugs.  
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1 INTRODUCTION 
Bacterial pneumonia (BP) has been recognized already from the early days of 
documented human history, as the clinicals signs associated with BP were 
described accurately by Hippocrates ca. 400 years BC (Pappas et al., 2008). 
Bacteria were first detected in the lungs of a person having died of pneumonia 
by Edwin Klebs in 1875 (Klebs, 1875), and soon after that, in the 1880s the 
most common causative organism in humans, Streptococcus pneumoniae, 
was identified (Friedländer, 1882). Despite rapid progress in human medicine 
and advanced intensive care facilities, pneumonia remains an important cause 
of death due to infectious diseases in the Western world (Nair and Niederman, 
2011). Pneumonia accounts for a large proportion of human healthcare 
resources; the global economic cost of pneumonia has been estimated at 17 
billion dollars annually (Nair and Niederman, 2011).  
In dogs bacterial pneumonia (BP) was also recognized decades ago. In the 
1910s and after that, reports were published of dogs serving as experimental 
models in attempts to shed light on human bacterial diseases (Lamar and 
Meltzer, 1912; Wollstein and Meltzer, 1912; Leake and Brown, 1922; Harrison 
and Blalock, 1926; Coggeshall and Robertson, 1935; Loosli, 1942; Dale et al., 
1974a). Naturally occurring BP in dogs was later described in connection with 
contagious respiratory diseases (Armstrong et al., 1972; Rosendal, 1972; Batey 
and Smits, 1976; Rosendal, 1978), and thereafter, clinical and microbiological 
findings in have been reported in retrospective studies (Thayer and Robinson, 
1984; Jameson et al., 1995; Wingfield, 1997; Radhakrishnan et al., 2007; 
Epstein et al., 2010; Proulx et al., 2014;).  
BP is currently considered one of the most common systemic bacterial 
infections in dogs, with a significant morbidity and risk of mortality (Ford, 
2009). However, several aspects of BP require further studies. Natural course 
of BP has not been described in longitudinal studies and prognostic factors are 
largely unknown. The etiology of BP is complex and multifactorial, and the role 
of preceding or concurrent viral infections in the development of BP in 
household dogs has not been established. Additionally, therapeutic aspects of 
BP in dogs are largely based on clinical experience and extrapolations from 
human medicine.  
Acute phase proteins (APPs) are sensitive markers of inflammation, and 
especially serum C-reactive protein (CRP) is currently an important diagnostic 
and follow-up marker in humans with community-acquired pneumonia (CAP) 
(FAU et al., 2007; Lim et al., 2009; Woodhead et al., 2011). CRP has been 
shown to be elevated in dogs with BP (Yamamoto et al., 1994b; Christensen et 
al., 2014), but the utility of serum CRP measurement as a diagnostic, 
prognostic, or follow-up marker in dogs with BP has not been studied.  
This thesis aims to further define clinical features during disease and the 
recovery period in naturally occurring BP in dogs, to evaluate the applicability 
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of APPs as diagnostic, prognostic, and follow-up markers, and to assess the 
role of viral co-infections. 
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2 REVIEW OF THE LITERATURE 
2.1 PULMONARY DEFENSE MECHANISMS 
Hundreds of liters of air move in and out of the respiratory tract of an adult 
middle-sized dog each hour. Inhalation is the most important route for 
pathogens to invade the respiratory system, followed by hematogenous spread 
and infection through a penetrating wound in the thoracic wall. A variety of 
elaborate defense mechanisms have evolved to protect the respiratory system. 
These defense mechanisms are highly effective in healthy animals, and 
therefore, primary respiratory tract infections are uncommon in adult dogs 
(Ford, 2009).  
2.1.1 DEFENSE MECHANISMS OF THE UPPER AIRWAYS 
In order for air to enter the respiratory tract, it must pass through the nasal 
passages or the mouth. The nasal passages comprise a large surface area in 
which large particles (>10 μm) can collide with the respiratory epithelium and 
may be entrapped in the mucous layer and get removed by the sneezing reflex 
or by ciliary movement (Brady, 2004). 
The pharynx is a common anatomic site for both respiratory and 
gastrointestinal systems and may therefore be considered a weak point in 
respiratory defense. During normal swallowing the respiratory tract is 
protected by the upward movement of the soft palate and the passive dorsal 
folding of the epiglottis (King, 1997). During vomiting and regurgitation the 
stimulation of the larynx results in a prompt closure of the arytenoid 
cartilages, preventing aspiration (King, 1997). Additionally, the gag reflex 
allows the removal of material from the pharynx.  
2.1.2 DEFENSE MECHANISMS OF THE TRACHEA, LOWER AIRWAYS, 
AND ALVEOLI 
In the airways, mechanical defense predominates and consists of the 
mucociliary escalator and the cough reflex. Particles larger than 3 μm tend to 
collide with bronchial walls and are removed by these mechanisms (Brady, 
2004). 
Mucociliary clearance 
The trachea, bronchi, and bronchioles are lined by ciliated epithelium, where 
each epithelial cell has numerous tiny cilia oriented in the same direction. 
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Mucus-producing goblet cells are present in smaller numbers between the 
ciliated epithelial cells (King, 1997). The function of the cilia is to move in a 
“whip-like” motion, propelling mucus and substances trapped in the mucous 
layer towards the pharynx, where they will be swallowed (Munkholm and 
Mortensen, 2014). 
The mucous layer surrounding the cilia consists of a watery periciliary layer 
and a superficial more viscous mucous layer touching only the tips of the cilia. 
The watery periciliary layer has two functions; due to its low viscosity, it allows 
the cilia to move and it also prevents the mucous layer from adhering to the 
epithelium (Munkholm and Mortensen, 2014). In healthy individuals, the 
mucous layer is composed of 97% water and 3% solids, allowing effortless 
clearance of respiratory secretions.  In addition to mucin, mucus-producing 
secretory cells produce several antimicrobial and immunomodulatory 
molecules (Munkholm and Mortensen, 2014). 
Cough reflex 
Cough is a nonspecific reflex in response to irritation of the trachea or bronchi. 
The cough reflex assists the mucociliary clearance in the removal of foreign 
particles and accumulated mucus from the airways.  
The reflex starts with the stimulation of cough receptors, which consist of 
sensory nerves (Rozanski and Rush, 2004). At least three different cough 
receptors exist; rapidly adapting stretch receptors, which are located in the 
mucosa of the tracheobronchial tree, and pulmonary and bronchial C-fibers, 
which are located close to blood vessels (Rozanski and Rush, 2004). Cough 
receptors may be stimulated by both mechanical and chemical factors. Stretch 
receptors react to light mechanical stimuli, whereas C-fibers are more 
sensitive to chemical stimulus (Rozanski and Rush, 2004).   
A cough begins with a deep inhalation followed by closure of the glottis and 
diaphragmatic contraction. Increased intrathoracic pressure is promptly 
released and the subsequent rapid air flow allows expulsion of large particles 
or mucus (King, 1997). 
Innate immune defenses 
When mechanical defenses fail to remove particles or microbes, innate 
immune defense is the next line of defense in the lungs (Cohn and Reinero, 
2007). Innate immune system does not require prior contact with the potential 
pathogen and comprises chemical defenses, complement and inflammatory 
cascades, and phagocytic and natural killer cells (Cohn and Reinero, 2007). 
The respiratory epithelium and submucosal glands produce several 
antimicrobial chemicals such as defensins, lactoferrin, lysozyme, and 
cathelicidins (Munkholm and Mortensen, 2014). 
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The major phagocytic cells of innate defense are neutrophils and 
macrophages, which bind, ingest, and destroy potential pathogens (Cohn and 
Reinero, 2007). Particles less than 2 μm in diameter, such as bacteria and 
viruses, may be carried with inhaled air into the alveoli. Alveolar macrophages 
(AMs) are the most numerous immune cells in the alveoli and are mainly 
responsible for the innate immune defense. The alveolar epithelium lacks 
mucociliary properties, and therefore, relies mainly on the AMs to remove 
particles and micro-organisms (Pilette et al., 2001).  AMs have differentiated 
from hematogenous monocytes and exhibit significant phenotypic and 
functional specialization (Byrne et al., 2015). The main functions of the AMs 
include removal of cellular debris and microbes by phagocytosis and secretion 
of cytokines in the activation of the inflammatory cascade as well as in the 
recruitment and activation of neutrophils (King, 1997).  
Lymphatic tissue and immunoglobulins 
The lung is a major lymphatic organ in the body. The main elements of the 
pulmonary lymphatic system comprise tracheobronchial and hilar lymph 
nodes as well as the lymphoid tissue loosely arranged as lymphoid nodules at 
the branching points of the small airways (King, 1997). This bronchus-
associated lymphoid tissue (BALT) is responsible for the production of most 
immunoglobulins in the respiratory secretions (Randall, 2010). The adaptive 
immune response requires several days to mature, but is highly pathogen-
specific and results in the development of immunological memory (Cohn and 
Reinero, 2007).   
Immunoglobulin A (IgA) inhibits the adherence of pathogens to the 
epithelium by specific IgA antibodies (Pilette et al., 2001). It has also been 
shown that IgA can neutralize infectious agents and interfere with bacterial 
plasmids encoding adherence or antibiotic resistance (Pilette et al., 2001). 
Research has identified receptors for IgA on the surface of blood leukocytes 
and AMs, indicating mechanisms of interaction between humoral and cellular 
immunity (Pilette et al., 2001). IgA is most important in the upper airways, 
whereas immunoglobulin G and immunoglobulin M are of greater importance 
in the lower airways and pulmonary parenchyma (Cohn and Reinero, 2007). 
They are both less effective in the exclusion of pathogens than IgA, but are 
important opsonins and effective when dealing with an established infection 
(Cohn and Reinero, 2007). 
2.2 MICROBIOLOGY OF THE HEALTHY CANINE LUNG 
Bacterial flora of the healthy canine lung was first subjected to experimental 
animal studies in the 1970s and 1980s, and these early studies concluded that 
 20 
the canine tracheobronchial tree is not always sterile (Pecora, 1976; Lindsey 
and Pierce, 1978; McKiernan et al., 1984).  
Pecora (1976) showed that bacteria were detected in healthy dogs using an 
enrichment culture method in 76% of transtracheal samples, in 34% of lung 
puncture samples, and in 63% of lung biopsy samples obtained during thoracic 
surgery. Later studies demonstrated bacteria slightly less often: in 36-47% of 
tracheal samples and in 37% of lung biopsy samples (Lindsey and Pierce, 1978; 
McKiernan et al., 1984). Lindsey and Pierce (1978) examined lung biopsies 
with a quantitative method and demonstrated that the mean bacterial 
concentration in healthy dogs was 1.2 x 103 organisms/gram of lung tissue.  
Bacterial species identified in healthy canine respiratory tract are shown in 
Table 1. Bacteria isolated in 78-80% of tracheal samples and in 74% of the lung 
biopsy samples were identical to the pharyngeal flora of the same animal 
(Lindsey and Pierce, 1978; McKiernan et al., 1984). This indicates that 
recurrent aspiration of the oropharyngeal flora could be a likely source of 
bacteria identified in the airways (McKiernan et al., 1984). This hypothesis is 
supported by the finding that bacteria were more often encountered in the 
trachea than in the lower respiratory tract (Lindsey and Pierce, 1978; 
McKiernan et al., 1984). 
 
 
Table 1 Prevalence of various bacterial species isolated in tracheal wash and lung 
biopsy specimens of healthy dogs. 
Pecora et al., 1976 
 
42 healthy dogs 
TTW, TTA, surgical sampling 
 
Enrichment culture method 
 
Lindsey and Pierce 1978 
 
19 healthy dogs 
Surgical sampling 
 
Quantitative culture method 
McKiernan et al. 1984 
 
33 healthy dogs 
ETW sampling 
 
Enrichment culture method 
 
Staphylococcus spp. 
 
25% 
 
Staphylococcus aureus 
 
Streptococcus spp.  
 
29% 
Enterobacter spp. 24% Klebsiella pneumoniae Staphylococcus spp.  16% 
B bronchiseptica  15% Enterobacter spp. Pasteurella multocida 11% 
Clostridium spp. 7% Acinetobacter spp. Klebsiella spp. 5% 
E. coli 5% Moraxella spp. Enterobacter spp. 4% 
Klebsiella spp. 5%  Corynebacterium sp. 2% 
Streptococcus spp. 3%  Pseudomonas spp. 2% 
Pseudomonas spp. 2%  B. bronchiseptica 2% 
   E. coli 2% 
TTW=transtracheal wash, TTA=transthoracic aspirate, ETW= endotracheal wash 
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Since bacterial cultures from the respiratory tract are important means to 
identify lower respiratory tract infections in canine patients, effort has been 
made to establish a quantitative cut-off to distinguish normal bacterial 
colonization of lower airways from actual bacterial infection.  
Bronchoalveolar lavage (BAL) is the main method in lung diagnostics, and 
a quantitative cut-off point for significant bacterial growth in bronchoalveolar 
lavage fluid (BALF) was assessed in two studies, which came to slightly 
different conclusions. Peeters et al. (2000) retrospectively examined patient 
records and compared quantitative bacterial culture findings in dogs with 
clinical signs typical of a lower respiratory tract infection with findings in dogs 
with clinical signs suggestive of chronic bronchitis or other non-infectious lung 
pathology. A cut-off set at 1.7 x 103 colony-forming units (CFU)/ml identified 
dogs with bacterial lower respiratory tract infections with a sensitivity of 86% 
and a specificity of 100% (Peeters et al., 2000).  
A later study by Hirt et al. (2010) identified significantly larger quantities 
of bacteria in healthy laboratory beagles when comparing the BALF obtained 
through a laryngeal mask with the BALF obtained through unprotected upper 
airways. The mean bacterial counts identified in this study were between 22.5 
x 103 and 25.6 x 103 CFU/ml. However, a study describing microbial culture 
findings in 13 healthy laboratory beagles (Melamies et al., 2011) did not detect 
bacterial growth (>x103 CFU/ml) in BALF. Cellularity of the BALF samples 
described by Hirt et al. (2010) were also higher (691.0-734.0 cells/μl) than the 
reference ranges described in other studies performed in healthy dogs 
(Rajamaki et al., 2002; Heikkila et al., 2011), suggesting that there could have 
been differences in the dog populations, sampling sites, or sampling methods.  
The site of sampling is likely to affect the quantitative bacterial culture 
findings in healthy dogs since bacteria are found more often in the trachea 
than in the lower airways. A quantitative cut-off point for transtracheal wash 
(TTW) samples in healthy dogs has not been described.  
2.3 CANINE BACTERIAL PNEUMONIA 
Bacterial pneumonia (BP) is an acquired inflammation of the lower airways 
and lung parenchyma caused by bacterial infection (Ford, 2009). In humans, 
community-acquired pneumonia (CAP) is a major cause of death due to 
infectious disease and has an estimated incidence of 12-18 cases/1000 persons 
per population per year (Coelho et al., 2007; Lippi et al., 2011). Although 
similar numbers are not available for canine patients, BP is considered to be 
one of the most common systemic bacterial infections, with significant 
morbidity and risk of mortality.  
Although BP is a common and well-known disease entity in dogs, a limited 
number of published reports describe the naturally occurring disease. The first 
reports describe BP in dogs infected with distemper or CIRD pathogens (Batey 
and Smits, 1976; Rosendal, 1978). Currently available publications are mainly 
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retrospective case series focusing on clinical characteristics and 
microbiological findings in BP (Thayer and Robinson, 1984; Jameson et al., 
1995; Wingfield, 1997; Radhakrishnan et al., 2007; Epstein et al., 2010; 
Sumner et al., 2011; Proulx et al., 2014).   In addition to reports on naturally 
occurring BP, some experimental studies using dogs as models in human 
research aimed at investigating the pathogenesis of BP and possible treatment 
options are available (Dale et al., 1974a; Dale et al., 1974b; Dale et al., 1976; 
Katz et al., 1980; Hicks et al., 2012; Cortes-Puch et al., 2014). 
The complexity of the etiology and pathogenesis of BP in both humans and 
dogs is acknowledged, and several aspects of the disease remain obscure. 
Especially prognostic factors, follow-up characteristics, and therapeutic 
aspects of BP have not been properly studied in dogs.  
2.3.1 RESPIRATORY TRACT SAMPLING 
Treatment of BP benefits from identifying the causative bacteria and its 
antimicrobial resistance profile. However, sampling must be weighed against 
the possible risks related to the procedure.  
Bronchoscopy and BAL are generally considered the most effective means 
of examining the respiratory system and collecting representative samples 
(Finke, 2013). In patients with BP, bronchoscopy allows identification of the 
most affected areas and collection of samples in the area where visible 
secretions are present. However, patients with BP have a varying degree of 
hypoxemia (Wingfield, 1997) and risks related to the general anesthesia 
required for the procedure need to be considered. Since the partial pressure of 
arterial oxygen (PaO2) may decrease transiently even in healthy dogs after 
BAL, the susceptibility of dogs with BP to marked hypoxemia following the 
procedure must be taken into account (Finke, 2013). 
Transtracheal wash (TTW) is an alternative method to BAL. It is a 
minimally invasive procedure used to sample the large airways. TTW is 
performed on conscious animals with local anesthesia and samples from the 
lower trachea are collected via a catheter passed through the cricothyroid 
ligament or between two tracheal rings (Creevy, 2009). Small amounts (10% 
or less) of wash fluid are usually retrieved (Finke, 2013). The main advantage 
of TTW in dogs with BP is that it can be performed without general anesthesia, 
and complications during the procedure are rare (Finke, 2013). However, 
since tracheal samples may not represent well the pathology in lower airways 
and lung parenchyma, the sensitivity and specificity of TTW samples is 
considered relatively poor (Moser et al., 1982). TTW sampling is not 
recommended in cats or small (<10 kg) dogs and may be substituted by 
endotracheal wash (ETW) sampling (Finke, 2013). However, ETW requires 
general anesthesia and endotracheal intubation, and therefore, the risks are 
comparable to bronchoscopy and BAL. Due to its better sensitivity and 
specificity, BAL is often preferred over ETW.  
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The applicability of transthoracic needle aspiration (TTA) has been 
evaluated in an experimental model of canine BP. The method has yielded a 
sensitivity of 90-100% in identification of the causative organism and a 
relatively low contamination rate (0-12%) (Moser et al., 1982). Unfortunately, 
TTA was associated with a 20-30% frequency of pneumothorax of varying 
severity (Moser et al., 1982).  Since dogs with BP are already affected with 
respiratory compromise, additional pneumothorax may markedly exacerbate 
clinical signs. Transbronchial needle aspiration was not useful in the diagnosis 
of BP in dogs with experimentally induced pneumonia (Shure et al., 1985). 
In humans, most respiratory cultures are performed from fresh sputum 
samples, mainly due to the invasiveness of other sampling methods. In dogs, 
the utility of deep oral swabs as a potential sampling method for respiratory 
cultures has been investigated, but the bacteria isolated in swabs correlated 
poorly with tracheal wash results (Sumner et al., 2011). 
2.3.2 MICROBIOLOGICAL FINDINGS 
Bacterial pneumonia is most often caused by opportunistic bacteria belonging 
to the normal oropharyngeal flora. Most commonly isolated bacteria are 
Gram-negative Escherichia coli and Pasteurella spp., followed by Gram-
positive cocci Streptococcus spp. and Staphylococcus spp. (Thayer and 
Robinson, 1984; Jameson et al., 1995; Angus et al., 1997; Wingfield, 1997). 
Detailed microbiological findings in the aforementioned studies are presented 
in Table 2. Primary bacterial pathogens belonging to the canine respiratory 
disease (CIRD) complex, such as Bordetella bronchiseptica, Mycoplasma 
spp., and Streptococcus equi sp. zooepidemicus (Str. zooepidemicus), have 
also been isolated in dogs with BP, especially when dogs were housed in an 
environment with increased infection pressure (Batey and Smits, 1976; 
Radhakrishnan et al., 2007; Zeugswetter et al., 2007; Pesavento et al., 2008; 
Priestnall et al., 2010).  
Microbiologal findings in dogs with aspiration pneumonia (AP) were 
described in a retrospective study by Tart et al. (2010). Of their samples, 77% 
were positive for bacterial growth and the distribution of bacteria was similar 
to that reported in dogs with BP without aspiration etiology (Tart et al., 2010).  
The prevalence of Mycoplasma spp. varies greatly, most likely due to the 
lack of specific culture methods for Mycoplasma spp.. Jameson et al. (1995) 
retrospectively viewed cases of BP where both aerobic and specific culture 
methods for Mycoplasma spp. were used.  Solely Mycoplasma spp. were 
detected in 7% of dogs and Mycoplasma spp. accompanied by other aerobic 
bacteria in 63% of dogs (Jameson et al., 1995). Mycoplasma spp. were isolated 
in 21% of dogs with AP (Tart et al., 2010). 
An infection with a single species of bacteria was encountered most often, 
in 57-74% of dogs (Thayer and Robinson, 1984; Angus et al., 1997). In dogs 
with AP, more than one species of bacteria was encountered slightly more 
often, in 45% of samples (Tart et al., 2010). More than one species was also 
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detected more frequently when Mycoplasma spp. were involved in the 
pathogenesis (Jameson et al., 1995).  
Isolated cases of BP caused by atypical bacteria, such as Nocardia asteroids 
and Mycobacteria spp., have been reported (Turnwald et al., 1988; Lobetti et 
al., 1993; Gay et al., 2000; Irwin et al., 2000; Leissinger et al., 2015). 
A lethal hemorrhagic pneumonia caused by E. coli has been described in 
four research dogs and one domestic dog in the USA (Handt et al., 2003 ; 
Breitschwerdt et al., 2005). All dogs presented with a rapidly deteriorating 
respiratory disease. Histopathological findings comprised intrapulmonary 
hemorrhage, fibrinopurulent exudate, necrosis of alveolar septae, and 
hemorrhagic pleural effusion (Handt et al., 2003 ; Breitschwerdt et al., 2005). 
In all cases, an extraintestinal E. coli strain isolated possessed a virulence 
factor called cytotoxic necrotizing factor -1 (CNF-1), well characterized in 
humans with extraintestinal pathogenic E. coli (ExPEC) infections (Handt et 
al., 2003 ; Breitschwerdt et al., 2005).  
Negative respiratory tract culture results occur frequently in humans with 
CAP: This has been reported in up to 60% of samples (FAU et al., 2007; Lim 
et al., 2009). Due to the retrospective nature of available canine studies, the 
prevalence of negative culture results in dogs with BP has not been 
consistently evaluated. Murphy et al. (1997) reported negative bacterial 
culture findings in 58% of dogs undergoing pulmonary lobectomy as treatment 
for pneumonia, while Proulx et al. (2014) reported negative bacterial culture 
results in 14% of dogs with a clinical diagnosis of BP.  
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Table 2 Microbiological findings in dogs with bacterial pneumonia. Transtracheal wash 
(TTW), endotracheal wash (ETW), and bronchoalveolar lavage (BAL) were used 
as sampling methods.  
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2.3.3 PREDISPOSING FACTORS 
The high prevalence of infections with opportunistic bacteria stresses the 
importance of predisposing factors in the development of BP. The 
physiological protective mechanisms in the lungs are relatively effective, and 
the development of BP usually requires debilitation of these pulmonary 
defense mechanisms. Several predisposing factor to the development of BP 
have been identified in dogs.  
Aspiration 
The predisposing factor most often reported is aspiration. The injury begins 
initially as an aseptic inflammation in the airways and pulmonary parenchyma 
(aspiration pneumonitis), where the severity of injury is highly dependent on 
the nature of the aspirated fluid (Schulze and Rahilly, 2012). The initial caustic 
tissue damage triggers the release of inflammatory cytokines and results in the 
necrosis of alveolar cells, bronchoconstriction, infiltration of neutrophils into 
the alveoli, increased mucus production, and increased vascular permeability 
(Schulze and Rahilly, 2012). These changes impair the pulmonary defense 
mechanisms and predispose to secondary infection via bacterial colonization. 
Conditions reported to predispose to AP include laryngeal dysfunction 
(MacPhail and Monnet, 2001; Mercurio, 2011; Bahr et al., 2014), esophageal 
motility problems (Dewey et al., 1997; McBrearty et al., 2011), recent 
anesthesia (Ovbey et al., 2014), and neurological disease (Fransson et al., 
2001; Java et al., 2009). Two retrospective studies have examined the 
prevalence of different predisposing factors in dogs with AP; esophageal 
dysfunction (in 17-40% of dogs) and vomiting (18-39%) were reported most 
commonly in both studies, followed by neurologic disease (11-27%), 
postanesthetic AP (14-16%), and laryngeal disease (10-18%) (Kogan et al., 
2008b; Tart et al., 2010). 
The prognosis for dogs treated for AP at university hospitals is relatively 
good; 77-82% of dogs are reported to survive to discharge with an average 
hospitalization of 3-5 days (Kogan et al., 2008b; Tart et al., 2010). The 
underlying disease process predisposing to aspiration did not affect survival 
to hospital discharge (Kogan et al., 2008b). Tart et al. (2010) concluded that, 
similar to humans, dogs with AP involving more than one lung lobe have a 
higher mortality rate. However, Kogan et al. (2008b) was unable to establish 
a connection between the extent of alveolar density in thoracic radiographs 
and prognosis. A statistical association with a specific medication or 
supportive treatment and survival has not been noted (Tart et al., 2010). 
An overall incidence of 0.5% has been reported for AP in a specialist animal 
hospital in Sydney, Australia (Greenwell and Brain, 2014). Greenwell et al. 
(2014) also suspected a possible breed predisposition in the Irish wolfhound 
based on the high prevalence of presumptive AP in this breed. However, due 
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to the retrospective nature of the study, aspiration etiology could not be fully 
confirmed in most cases.  
Ciliary defects 
Mucociliary clearance is a critically important feature in pulmonary defense, 
facilitating the removal of secretions and foreign material from the airways. 
Repeated BP due to primary ciliary dyskinesia (PCD) is identified in dogs 
(Dhein et al., 1990; Watson et al., 1999, Merveille et al., 2014).  
Since PCD in an uncommon disease, existing research data comprises 
mainly isolated case reports and case series describing clinical findings. In a 
recent genetic study by Merveille et al. (2014), the prevalence of 
bronchopneumonia in Old English Sheepdogs with primary ciliary dyskinesia 
was 100%.  
Immune deficit 
Bacterial pneumonia is commonly encountered in dogs with congenital or 
acquired immune deficit (Blum et al., 1985; Breitschwerdt et al., 1987; 
Trowald-Wigh et al., 2000). In addition to the commonly encountered 
bacteria in BP, dogs with dysfunction of the immune system may present with 
atypical pathogens of low pathogenicity such as Pneumocystis caninii 
(Lobetti, 2000; Kanemoto et al., 2015). 
Other predisposing factors 
Chronic structural changes in the airways that debilitate function of the 
mucociliary escalator, such as chronic bronchitis and bronchiectasis, can 
predispose to BP. Secondary bacterial infections are frequently encountered in 
dogs with bronchiectasis (Johnson et al., 2016). 
Rare congenital defects, such as bronchoesophageal and 
tracheoesophageal fistulas, enable the passage of fluid and ingested food 
material to the lungs and are associated with secondary BP (Della Ripa et al., 
2010; Kaminen et al., 2014). Tracheobronchial foreign bodies may also cause 
secondary BP (Caywood et al., 1985; Cerquetella et al., 2013). 
Viral infections are also regarded as predisposing factors for secondary BP 
in dogs (Johnsson, 2010). However, most published reports describe viral 
infections and BP in dogs living under increased infection pressure (e.g. living 
in kennels or rescue shelters), and currently there is very little information on 
the role of viral infections leading to BP in household dogs.  
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2.3.4 CLINICAL FINDINGS 
Signalment and clinical signs 
Bacterial pneumonia can affect dogs of all sizes and ages, but it has been 
reported that young medium-sized and large breed dogs are more often 
affected (Thayer and Robinson, 1984). Thayer and Robinson (1984) reported 
a male predisposition in dogs with BP, however, later studies did not find 
differences in gender distribution (Jameson et al., 1995; Wingfield, 1997). 
Most common signs of BP are cough (57%), depression (50%), and anorexia 
(36%). Dyspnea was observed in 33% of dogs with BP (Thayer and Robinson, 
1984). Although BP is caused by a bacterial infection, fever was encountered 
in less than half of the dogs (Thayer and Robinson, 1984; Kogan et al., 2008a). 
Increased respiratory rate as well as increased breathing sounds or crackles on 
auscultation were encountered in most dogs (Thayer and Robinson, 1984). 
Hemoptysis has been reported to occur most commonly in dogs with BP 
(Bailiff and Norris, 2002). Severe BP may develop into acute respiratory 
distress syndrome and respiratory failure (Parent et al., 1996). 
Laboratory findings 
Since BP is most often a rapidly developing severe bacterial infection, the 
extravasation of neutrophils into lung parenchyma may affect markedly the 
findings in peripheric blood leukogram. The most common changes in 
leukogram were left shift (in 39-69% of dogs), leukocytosis (66%), and 
neutrophilia (52-69%) (Thayer and Robinson, 1984; Jameson et al., 1995). 
Since changes are not consistently present in dogs with BP, a normal 
hemogram cannot be applied to rule out BP.  
 The accumulation of secretions and inflammatory cells in the alveoli leads 
to ventilation-perfusion mismatch and shunting, resulting in hypoxemia of 
varying severity (Wingfield, 1997). Wingfield (1997) reported a significantly 
lower PaO2 (mean 61.4 ± SD 12.2 mmHg) and an elevated alveolar arterial 
oxygen gradient (A-aO2) (mean 26.8 ± SD 16.3) in dogs with BP compared with 
healthy dogs. Hypoxemia of a similar degree was reported in dogs with AP 
(Kogan et al., 2008a). Elevated serum C-reactive protein (CRP) has been 
reported in dogs with BP (Yamamoto et al., 1994b), and elevated serum 
amyloid A (SAA) has been described in dogs with AP (Christensen et al., 2014).  
Thoracic imaging 
Thoracic radiographs are considered critical for the diagnosis of BP. An 
alveolar pattern is the hallmark of BP, but also an interstitial pattern or even 
normal thoracic radiographs may be encountered early in the disease (Brady, 
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2004; Ford, 2009; Dear, 2014). Detailed radiographical findings have been 
reported only in dogs with AP (Eom et al., 2006; Kogan et al., 2008a; Tart et 
al., 2010) and in dogs with BP caused by Mycoplasma spp. (Jameson et al., 
1995).  
Radiographic findings in AP were reported by Kogan et al. (2008a) in 88 
dogs and by Tart et al. (2010) in 115 dogs, comprising an alveolar pattern in 
74% and 69% and an interstitial pattern in 26% and 14% of dogs, respectively. 
Of  the dogs, 52% and 39% had one lung lobe affected; the rest of the dogs had 
several lung lobes affected, the most frequently affected areas being the right 
middle lung lobe (48% and 70%), right cranial lobe (38% and 39%), left 
cranial-caudal segment (38% and 40%), and left cranial-cranial segment (31% 
and 40%) (Kogan et al., 2008a; Tart et al., 2010). 
Jameson et al. (1995) found an alveolar pattern in 45% of dogs with BP 
caused by Mycoplasma spp., and 9% of thoracic radiographs were interpreted 
as normal. 
Respiratory samples 
The respiratory cytology in dogs with BP has been described exclusively in 
TTW samples. Neutrophilic inflammation is most commonly encountered in 
66-74% of dogs (Thayer and Robinson, 1984; Jameson et al., 1995). 
Intracellular bacteria were reported in 48% of dogs (Thayer and Robinson, 
1984). 
The clinical value of BALF enzymatic markers and biochemical values was 
investigated by Maden et al. (2001) in 12 dogs with BP. BALF concentrations 
of lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) were 
significantly increased in dogs with BP, and the authors suggested these 
parameters as useful markers of lung inflammation (Maden et al., 2001). 
Concentrations of BALF calcium and zinc are elevated and that of phosphorus 
is decreased in dogs with BP compared with healthy controls, but the clinical 
applications of these findings are unclear (Suzuki et al., 2008). 
Treatment 
The treatment regimens in dogs with BP have been largely adopted from 
human medicine, and the regimens have not yet been subjected to any clinical 
trials.  
The mainstay of treatment in BP, as in all systemic bacterial infections, is 
antimicrobials. Antimicrobial treatment should be initiated without delay and 
respiratory sampling should be performed, if possible, prior to initiation of 
therapy. Since culture results are available after 1-2 days, the initial antibiotics 
need to be chosen empirically. In humans with CAP, administration of 
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antibiotics is recommended within 4 hours of presentation to hospital; elays 
are known to worsen prognosis (Lim et al., 2009). 
Antibiotic susceptibility of bacterial isolates from dogs with respiratory 
diseases has been evaluated in retrospective studies. Rheinwald et al. (2015) 
reported a susceptibility of 87% to enrofloxacillin and 59% to amoxicillin-
clavulanic acid among Gram-negative bacteria. Of Gram-positive bacteria, 
92% were susceptible to amoxicillin-clavulanic acid and 83% to enrofloxacin 
(Rheinwald et al., 2015). Proulx et al. (2014) found that in 26% of dogs with 
BP bacteria isolated in tracheal samples were resistant to the empirically 
selected antimicrobials. In vitro bacterial resistance was more common to 
those antimicrobials that were recently administered (Proulx et al., 2014).  
Epstein et al. (2010) studied antibiotic susceptibility in dogs with respiratory 
infections of varying severity and concluded that patients with severe 
respiratory failure were more likely to have bacterial isolates resistant to the 
commonly used antimicrobials. 
In addition to antibiotics, supportive therapy generally comprises oxygen 
supplementation and fluid therapy (Brady, 2004). To aid removal of 
respiratory secretions, saline nebulization and coupage can be applied (Brady, 
2004). 
Murphy et al. (1997) evaluated pulmonary lobectomy as a treatment 
modality in dogs with BP of various etiology. A relatively high perioperative 
mortality rate was noted (20%), and the resolution rate of pneumonia in 
survivors was low (54%). Surgical lobectomy was most successful in dogs with 
foreign body pneumonia, where 75% of dogs had resolution of the disease 
(Murphy et al., 1997). 
Therapy with granulocyte transfusions has been shown to be beneficial in 
leukopenic dogs with an experimentally induced pneumonia (Dale et al., 
1974b; Dale et al., 1976).  
The function of the hypothalamic-piltuitary-adrenal axis and possible 
benefits of corticosteroid medications in severe pneumonia have been 
evaluated in experimental canine models. Hicks et al. (2012) showed a 
beneficial effect of stress doses of desoxycorticosterone and dexamethasone in 
experimental pneumonia and sepsis caused by Staphylococcus aureus. 
Pretreatment with a high dose of methylprednisolone worsened the prognosis 
in an experimentally induced canine Pseudomonas spp. pneumonia (Katz et 
al., 1980). In humans with CAP, adjunctive corticosteroid treatment reduces 
the length of hospitalization and the number of severe complications (Marti et 
al., 2015). However, the effect on mortality remains uncertain (Marti et al., 
2015). 
2.4 CANINE INFECTIOUS RESPIRATORY DISEASE  
Canine infectious respiratory disease (CIRD) is a contagious respiratory 
disease with a multiorganism etiology. CIRD, also called infectious 
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tracheobronchitis or kennel cough, is one of the most common infectious 
diseases in dogs worldwide. CIRD is highly contagious and is most prevalent 
in dense dog populations such as in kennels and rehoming centers 
(Buonavoglia and Martella, 2007). CIRD affects the larynx, trachea, bronchi, 
and also rarely the nasal mucosa, causing acute respiratory signs, mainly 
cough, which are usually self-limiting (Buonavoglia and Martella, 2007). CIRD 
has a multifactorial etiology; several respiratory viruses as well as selected 
bacterial pathogens have been shown to contribute to the disease complex 
(Priestnall et al., 2014). Infections with multiple CIRD organisms generally 
cause a more severe clinical disease than an infection with a single CIRD 
pathogen (Appel and Percy, 1970; Wagener et al., 1984). 
CIRD has attracted considerable interest in recent years, and several novel 
pathogens have been identified in the 21st century. However, at present most 
studies addressing CIRD describe outbreaks in dense dog populations. The 
prevalence, epidemiology, and pathophysiology of CIRD as well as the role of 
vaccinations in the prevention of CIRD remain largely unknown in household 
dogs.  
2.4.1 RESPIRATORY VIRUSES IN CIRD 
Canine parainfluenza virus 
Simian virus 5 (SV-5), currently known as canine parainfluenza virus (CPIV), 
was first described in dogs with contagious respiratory disease already in the 
1960s (Binn et al., 1967; Crandell et al., 1968). Thereafter, CPIV has been 
shown to be a prevalent etiologic agent in CIRD worldwide (Binn et al., 1968; 
Erles et al., 2004; Mochizuki et al., 2008; Ellis et al., 2011; Schulz et al., 2014). 
CPIV was detected with a PCR method in 38% of dogs with clinical signs 
suggestive of CIRD in Germany (Schulz et al., 2014) and in 7% of dogs with 
CIRD signs in Japan (Mochizuki et al., 2008).  
In dogs infected with CPIV, symptoms generally occur 2-8 days post-
infection and usually last for less than six days (Ellis and Krakowka, 2012). 
CPIV is excreted from the respiratory tract of infected animals for 8-10 days 
(Buonavoglia and Martella, 2007). Already the early epidemiologic studies 
showed that an infection with CPIV alone resulted in mild to moderate upper 
respiratory signs, and that signs were more severe when dogs were 
simultaneously infected with other respiratory viruses such as Bordetella 
bronchiseptica or Mycoplasma spp. (Appel and Percy, 1970; Binn et al., 1979).  
The first CPIV vaccines were introduced in the 1970s, and currently both 
intranasal and parenteral CPIV vaccines are widely used. The efficacy of both 
vaccine types has been demonstrated in mainly experimental studies (Ellis and 
Krakowka, 2012). For reasons not fully understood, despite the widespread 
use of vaccinations, CPIV remains one of the most frequently encountered 
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viral agents in CIRD (Erles et al., 2004; Mochizuki et al., 2008; Schulz et al., 
2014). An outbreak of nosocomial CPIV infection has been described in a 
veterinary hospital (Weese and Stull, 2013). 
Canine adenovirus 
Canine adenovirus type 2 (CAV-2) was first isolated in dogs affected by a 
laryngotracheitis in Canada in 1961 (Ditchfield et al., 1962). The clinical signs 
comprised a mild increase in body temperature and a dry hacking cough. 
Conjunctivitis was noted in a minority of dogs (Ditchfield et al., 1962). CAV-2 
replicates in mucosal cells in the nasal cavity, pharynx, trachea, and bronchi. 
The viral replication peak is reached by 3-6 days after infection, and usually 
CAV-2 cannot be isolated beyond 9 days’ post-infection (Buonavoglia and 
Martella, 2007). Dogs exposed only to CAV-2 may not show spontaneous 
respiratory disease, but when additional viral or bacterial pathogens are 
involved, clinical signs of a respiratory disease are generally observed 
(Buonavoglia and Martella, 2007). Severe secondary bacterial pneumonia has 
been reported in conjunction with adenoviral infections (Ditchfield et al., 
1962; Damian et al., 2005; Chvala et al., 2007; Almes et al., 2010). 
The host range of CAV-2 includes a variety of mammalian species, and wild 
animals may be a source of infection to dogs (Buonavoglia and Martella, 
2007). CAV-2 is a close relative of canine adenovirus type 1 (CAV-1), causing 
canine contagious hepatitis, with nucleotide identity of approximately 75% 
(Morrison et al., 1997). Vaccination against CAV-2 provides protection against 
both CAV-1 and CAV-2, likewise CAV-1 vaccinations protect against both 
viruses (Buonavoglia and Martella, 2007). Modified live CAV-2 vaccines have 
proven to be highly effective in reducing the prevalence of CAV-2 in the canine 
population. Currently, CAV-2 is only rarely found in dogs with CIRD (Erles et 
al., 2004; Mochizuki et al., 2008; Schulz et al., 2014). 
Canine herpesvirus 
Canine herpesvirus (CHV) was also detected in dogs with respiratory signs 
decades ago, but its role in CIRD remains controversial. There is evidence that 
CHV contributes to CIRD in dogs; CHV has been detected in the respiratory 
tract of sheltered dogs with respiratory signs (Erles et al., 2004), and 
seroconversion to CHV has been demonstrated in dogs after introduction to a 
kennel environment (Erles and Brownlie, 2005).  However, since dogs can 
remain latently infected, CHV detected in kennel dogs may represent 
reactivation of a latent CHV infection during stress rather than an entirely new 
infection.  
Generally, the pathogenicity of CHV has been considered low in adult dogs. 
In naturally infected dogs, respiratory signs varying from subclinical infection 
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to mild tracheobronchitis have been described (Karpas et al., 1968). 
Additionally, early experimental infections in young laboratory dogs resulted 
in either mild clinical signs of rhinitis and pharyngitis or inapparent infections 
(Appel et al., 1969). CHV can cause a fatal generalized disease in puppies less 
than two weeks of age, but infections in older animals appear to be restricted 
to the respiratory tract (Carmichael et al., 1965; Appel et al., 1969). After both 
symptomatic and asymptomatic infections, dogs can remain latently infected 
and excrete CHV periodically over several months or years. Reactivation of the 
virus can be triggered by stress or immunosuppression (Buonavoglia and 
Martella, 2007).  
Serological surveys indicate that CHV is highly prevalent in the canine 
population; antibodies against CHV were detected in 88% of dogs in England, 
in 46% in Belgium, and in 39% in the Netherlands (Reading and Field, 1999; 
Rijsewijk et al., 1999; Ronsse et al., 2002).  
Contrary to the commonly reported low pathogenicity of CHV, sporadic 
fatal CHV infections in adult dogs were recently described and a strain of high 
virulence suspected (Gadsden et al., 2012; Kumar et al., 2015). CHV can also 
cause significant disease in adult dogs with altered immune defense; a 
nosocomial outbreak of CHV among immunocompromised patients caused 
severe disease in a veterinary hospital in Japan (Kawakami et al., 2010).    
Canine respiratory coronavirus 
Canine respiratory coronavirus (CRCoV) was first found in 2003 in a 
rehoming center in the United Kingdom. The facility suffered from ongoing 
respiratory disease despite regular vaccinations, and when extensive 
examinations in order to identify the source of infections were carried out 
CRCoV was discovered (Erles et al., 2003). Coronaviruses had been described 
previously in dogs with gastroenteritis, but CRCoV proved to be distinct from 
canine enteric coronaviruses, showing only 69% nucleotide identity (Erles and 
Brownlie, 2008).  
Dogs with CRCoV infection present generally with mild respiratory disease 
characterized by dry cough and nasal discharge (Erles et al., 2004; Erles and 
Brownlie, 2005). Since CRCoV was detected in the 21st century, experimental 
animal studies describing the pathogenesis have not been reported, and all 
studies note CRCoV in naturally occurring CIRD. Therefore, it needs to be 
emphasized that currently available literature describing CRCoV reflects more 
the pathogenesis of multifactorial CIRD than an isolated CRCoV infection.  
The discovery of CRCoV initiated prevalence investigations worldwide. 
Antibodies against CRCoV were demonstrated in 55% of dogs in North 
America, in 36% in England, in 23% in Italy, and in 13% in South-Korea 
(Priestnall et al., 2006; Priestnall et al., 2007; An et al., 2010). The earliest 
evidence of a CRCoV infection in dogs was found in a Canadian post-mortem 
sample from 1996 (Ellis et al., 2005). 
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CRCoV appears to be a significant causative agent in CIRD. Schulz et al. 
(2014) reported CRCoV using a PCR method in 9% of upper respiratory tract 
samples in dogs with CIRD in Germany.  A similar study in Japanese dogs with 
CIRD detected CRCoV in 2% of dogs (Mochizuki et al., 2008).  
At present, vaccines against CRCoV infection are not yet available on the 
market, but vaccine manufacturing is expected in the future. 
Canine influenzavirus 
Experimental and natural infections of dogs by human influenza viruses 
(H3N2) have been demonstrated from the 1970s onwards, but transmission 
within the canine population was not identified (Kilbourne and Kehoe, 1975; 
Romvary et al., 1975). Similarly, equine influenza virus (H3N8) has caused 
respiratory disease in dogs that were in close proximity to horses during an 
outbreak of equine influenza, but dog-to-dog transmission was not observed 
(Daly et al., 2008; Kirkland et al., 2010) 
In 2004, a newly identified virus was isolated during an outbreak of 
respiratory disease in racing greyhounds in Florida. This virus proved to be an 
influenza virus originating from equine lineage (H3N8), and evidence emerged 
that this canine influenza virus (CIV) was capable of transmission from one 
dog to another (Crawford et al., 2005). Later studies showed that CIV is 
widespread among racing greyhounds and also pet dogs in the USA (Crawford 
et al., 2005; Anderson et al., 2013; Wiley et al., 2013). Retrospectively, 
evidence of the first CIV infections in greyhounds was detected as early as 1999 
(Anderson et al., 2012). 
The clinical picture of CIV infection is similar to that of other CIRD 
pathogens. The onset of clinical signs occurs 2-5 days post-infection and 
includes lethargy, low-grade fever, and dry cough that may last for several 
weeks (Dubovi and Njaa, 2008). Dogs of all ages appear susceptible and the 
morbidity rates described (60-80%) are high relative to other CIRD pathogens 
(Dubovi and Njaa, 2008). Secondary BP has been commonly described in dogs 
with CIV infections, and BP contributes often to the severe forms of the 
disease. Fatal hemorrhagic pneumonia has been described in dogs with 
simultaneous streptococcal infections (Crawford et al., 2005; Dubovi and 
Njaa, 2008). A vaccine against CIV has been developed (Larson et al., 2011). 
Canine pneumovirus 
Canine pneumovirus (CnPnV) is the most recent novel CIRD virus, discovered 
originally in 2010 in dogs with respiratory disease in two animal shelters in 
the USA (Renshaw et al., 2010). After the initial discovery, CnPnV has been 
detected by PCR methods in dogs with generally a mild respiratory disease in 
several locations in the USA as well as in the United Kingdom and in Italy 
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(Renshaw et al., 2011; Mitchell et al., 2013; Decaro et al., 2014). 
Seroprevalence of 50% was established in the United Kingdom and Northern 
Ireland (Mitchell et al., 2013). 
CnPnV is a close relative of well-known respiratory pathogens, including 
the murine pneumovirus as well as the bovine and human respiratory syncytial 
viruses (Renshaw et al., 2011). Despite the evident prevalence of CnPnV in 
dogs with respiratory disease, the role as a causative agent in CIRD has not yet 
been thoroughly evaluated. CnPnV has been shown to replicate and elicit 
inflammatory pathology in mice (Percopo et al., 2011), but the pathogenesis in 
dogs remains to be investigated in the future.  
2.4.2 BACTERIAL PATHOGENS IN CIRD 
In addition to viral agents, selected primary bacterial pathogens have been 
shown to contribute to the etiology of CIRD.  
Bordetella bronchiseptica 
Bordetella bronchiseptica is a primary respiratory pathogen in dogs that is 
capable of causing respiratory disease without an initiating viral infection 
(Bemis et al., 1977). However, B. bronchiseptica is also the most frequently 
identified bacterial organism in CIRD, and simultaneous infections with B. 
bronchiseptica and other pathogens such as CPIV, CAV-2, CHV, CRCoV, and 
Mycoplasma spp. are common (Appel and Percy, 1970; Wagener et al., 1984; 
Schulz et al., 2014).  
B. bronchiseptica has several mechanisms that allow the organism to avoid 
host defenses and that enhance pathogenicity. Fimbriae and the production of 
hemagglutinins and adhesins enable the bacteria to adhere to ciliated 
epithelium, and the production of exotoxins suppresses local immunity and 
contributes to the loss of ciliary function (Keil and Fenwick, 1998). B. 
bronchiseptica also has the ability to enter nonphagocytic cells, and this 
feature offers protection from the host immune system (Keil and Fenwick, 
1998). 
Productive cough and mucopurulent nasal discharge, appearing 2-10 days 
post-infection, are hallmarks of B. bronchiseptica infection (Bemis et al., 
1977). In experimental infections, clinical signs were self-limiting and lasted 
from a few days to two weeks (Bemis et al., 1977). However, chronic cough 
lasting for several months has later been reported in naturally infected dogs 
(Johnson et al., 2013). Typically, B. bronchiseptica infection did not induce 
elevations in body temperature or white blood cell counts (Bemis et al., 1977). 
Despite the short duration of signs in experimental infections, B. 
bronchiseptica bacteria were isolated in the trachea as long as 6-14 weeks after 
the infection (Bemis et al., 1977).  
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Since most B. bronchiseptica infections are mild and self-limiting, 
antimicrobial treatment is only warranted in cases of overt clinical signs or 
chronic cough lasting for several weeks (Bemis, 1992). Modified live B. 
bronciseptica vaccines are available for intranasal administration. Intranasal 
vaccines have been shown to induce significant levels of secretory antibodies 
as soon as 4 days after administration and to offer a protective effect lasting 
for at least 12 months (Bey et al., 1981; Lehar et al., 2008). 
A severe form of B. bronchiseptica infection leading to bronchopneumonia 
has been described in puppies aged less than one year (Radhakrishnan et al., 
2007). Puppies with BP caused by B. bronchiseptica were significantly 
younger (median 14 weeks) than puppies with BP caused by opportunistic 
bacteria and had a significantly longer period of hospitalization (mean 7 days). 
Altogether 94% survived to discharge, and survival did not differ from BP 
caused by other pathogens (Radhakrishnan et al., 2007). 
Mycoplasma spp.  
Mycoplasmas are bacteria that lack a cell wall and are enclosed by a lipid 
membrane. Mycoplasmas belong to the normal oropharyngeal flora in dogs 
and may be encountered also in the lower respiratory tract of healthy animals 
(Randolph et al., 1993).  
Whether Mycoplasma spp. can cause respiratory disease in dogs remains 
elusive. Mycoplasma spp. have been isolated from the lower respiratory tract 
in dogs with CIRD and BP as well as in dogs with noninfectious respiratory 
diseases (Armstrong et al., 1972; Randolph et al., 1993; Chalker et al., 2004; 
Zeugswetter et al., 2007). Several different species have been identified in 
dogs, and notable variation between individual species is likely (Rosendal, 
1978; Chalker et al., 2004). Experimental infection with M. cynos induced an 
inflammatory response in one-week-old puppies, whereas experimental 
infections with M. canis, M. gateae, and M. spumans failed to produce clinical 
respiratory disease (Rosendal, 1978). 
M. cynos has also been shown to contribute to spontaneous CIRD. Rycroft 
et al. (2007) reported that 67% of dogs showed a significant antibody response 
to M. cynos after introduction to a large rehoming kennel, and 80% of these 
dogs had simultaneous respiratory disease. Chalker et al. (2004) detected a 
diverse range of Mycoplasma species in kenneled dogs with and without 
CIRD, however, only M. cynos was significantly associated with respiratory 
disease. Infections with M. cynos were more likely in dogs under one year of 
age (Chalker et al., 2004). The connection between Mycoplasma infection and 
young age has been shown also in other studies; Randolph et al. (1993) 
investigated the prevalence of Mycoplasma spp. in dogs with any pulmonary 
disease and found also that Mycoplasma spp. were more often seen in dogs 
under one year of age. Additionally, a significant association was noted with 
simultaneous infections with Mycoplasma spp. and B. bronchiseptica 
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(Randolph et al., 1993). This finding was considered likely to be due to the high 
prevalence of CIRD in young dogs.  
Mycoplasma spp. were first isolated from the lungs of a dog with BP in 1972 
(Rosendal, 1972). After this initial discovery, Mycoplasma spp. have been 
frequently encountered in dogs with BP (Bemis, 1992; Jameson et al., 1995; 
Wingfield, 1997; Angus et al., 1997; Chvala et al., 2007). The definitive role of 
Mycoplasma spp. in BP is challenging to determine since generally 
Mycoplasma spp. are accompanied by other bacteria or viruses (Jameson et 
al., 1995; Priestnall et al., 2014). Therefore, it is unknown whether 
Mycoplasma spp. infection contributes to the pathogenesis of BP, or whether 
the pulmonary pathology in BP only predisposes the dog to Mycoplasma spp. 
colonization.  
In BP, a very limited number of studies have addressed the role of 
Mycoplasma spp.. Jameson et al. (1995) stated that history, clinical findings, 
and thoracic radiographs were similar in Mycoplasma-positive and 
Mycoplasma-negative dogs with BP (Jameson et al., 1995). A minor role of 
Mycoplasma spp. in the pathogenesis of BP was also suggested by the finding 
that the resolution of BP was unaffected by failure to treat Mycoplasma-
positive dogs with drugs efficient against Mycoplasma spp. (Jameson et al., 
1995).  
Contrary to the generally benign course of Mycoplasma spp. infections in 
dogs, Zeugswetter et al. (2007) described an outbreak of contagious M. cynos 
infection leading to lethal bronchopneumonia in young retriever puppies. M. 
cynos was cultured solely from lung samples, and viral infections with canine 
distemper virus, CHV, and CAV-1 as well as CAV-2 were excluded 
(Zeugswetter et al., 2007). However, other factors besides M. cynos infection 
may have had an impact on the severe outcome; these puppies had a 
simultaneous heavy ascarid infection and the role of possible CPIV infection 
was not addressed.  
Streptococcus equi sp. zooepidemicus 
Streptococcus equi sp. zooepidemicus (Str. zooepidemicus) has been 
recognized as a sporadic cause of contagious respiratory disease in dogs 
already decades ago (Garnett et al., 1982). During the last ten years an 
increasing number of reports have described outbreaks of an acute severe, 
often fatal, respiratory disease attributed to Str. zooepidemicus infection (Kim 
et al., 2007; Byun et al., 2009; Pesavento et al., 2008). Affected dogs showed 
rapidly progressing respiratory distress, hypovolemia, pyrexia, and 
hemorrhagic oral or nasal discharges. Dogs often deteriorated rapidly and died 
within 24-48 hours (Kim et al., 2007). Peracute deaths without any preceding 
clinical signs have also been reported in kenneled dogs (Garnett et al., 1982). 
Even early appropriate antimicrobial therapy may not be sufficient to stop the 
initiation of the inflammatory cascade leading to multiorgan dysfunction. 
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Pulmonary edema and hemorrhage were the main features detected in post-
mortem examination. In addition, a marked amount of hemorrhagic pleural 
effusion was often present (Pesavento et al., 2008; Byun et al., 2009). 
Currently, insufficient data exists to determine the factors causing this 
apparent virulence of Str. zooepidemicus. Certain superantigen-encoding 
genes, known to aggravate streptococcal disease in humans, have been 
identified in the Str. zooepidemicus strains isolated from dogs, but the 
influence in disease severity in dogs is currently unknown (Paillot et al., 2010). 
The bacteria is evidently able to spread between dogs, especially in dense 
populations; dogs in contact with affected dogs or their secretions frequently 
developed pneumonia or a milder respiratory disease characterized by 
purulent nasal discharge and tonsillitis (Garnett et al., 1982). The genetic 
analysis of different Str. zooepidemicus strains has demonstrated that some 
strains isolated from distinct geographic locations were closely related to each 
other (Webb et al., 2008). Other canine strains are related to equine strains, 
indicating that horses may serve as reservoirs of the bacteria and infect dogs 
in close contact with horses (Priestnall and Erles, 2011). 
Outbreaks of Str. zooepidemicus are almost exclusively described in dogs 
housed in dense populations, and it is likely that stress and elevated infection 
pressure play a role in the development of the disease. Jaeger et al. (2013) 
recently described Str. zooepidemicus infection in a pack of athletic sledge 
dogs, where the stress of endurance racing and a recent CIRD vaccination had 
likely contributed to the development of the disease. Str. zooepidemicus has 
only been sporadically detected in household dogs with respiratory disease 
(Chalker et al., 2003; Gibson and Richardson, 2008).  
Simultaneous co-infections with other CIRD pathogens, seen frequently in 
kenneled populations, are considered to influence the severity of the disease. 
Viral co-infections have frequently been reported in connection with Str. 
zooepidemicus infection and are likely to aggravate the disease (Garnett et al., 
1982; Yoon et al., 2005; Pesavento et al., 2008). This idea is supported by 
Larson et al. (2011), who described reduced disease severity in CIV-vaccinated 
dogs experimentally challenged with CIV and Str. zooepidemicus. 
Chalker et al. (2003) investigated the association between CIRD and Str. 
zooepidemicus in a large re-homing kennel known to suffer from endemic 
respiratory disease. Str. zooepidemicus was isolated from the lungs of 22% of 
the dogs, and the detection was associated with increasing severity of 
respiratory disease. However, a significant proportion of dogs with Str. 
zooepidemicus presented with only mild to moderate respiratory signs (cough, 
nasal discharge), and some dogs had no clinical signs (Chalker et al., 2003). 
This finding demonstrates that dogs with a Str. zooepidemicus infection may 
develop respiratory disease indistinguishable from that caused by other CIRD 
pathogens, and factors likely related to infection pressure, bacterial virulence, 
and host immune defense will account for the development of severe 
hemorrhagic pneumonia.  
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2.4.3 RESPIRATORY VIRUSES PREDISPOSING TO BACTERIAL 
INFECTIONS 
In humans, the association between respiratory viruses and the development 
of bacterial pneumonia first received attention in the 1918 influenza pandemic, 
when 40 to 50 million people died and many of them were lost due to 
secondary BP (Peltola and McCullers, 2004). Later, epidemiological studies 
have been able to show a link between outbreaks of respiratory viruses and the 
increased occurrence of BP; a significant increase in the prevalence of BP has 
been shown during outbreaks of influenza (Joseph et al., 2013) and Kim et al. 
(1996) demonstrated a seasonal association between viral respiratory 
infections (influenza and respiratory syncytial virus) and pneumococcal 
invasive disease. Additionally, the fact that vaccination against influenza 
effectively prevented bacterial otitis media in children suggests that viruses 
play a role in predisposing to secondary bacterial infections (Heikkinen et al., 
1991). 
Experimental studies have addressed the changes in bacterial colonization 
on the respiratory epithelium during viral infections. Most studies have 
measured bacterial adherence subsequent to viral infection in various cultured 
cell lines. The majority of these studies concluded that prior infection with 
respiratory virus enhanced bacterial adhesion (Hament et al., 1999). Several 
mechanisms have been suggested to contribute to increased bacterial 
adherence during viral infections; physical damage to the respiratory 
epithelium and loss of cilia may facilitate bacterial adhesion, virus-induced 
immunosuppression may further enhance bacterial infections, and 
inflammatory response to viruses may also upregulate expression of molecules 
that bacteria may utilize as receptors (Peltola and McCullers, 2004).  
Co-infections with respiratory viruses are increasingly identified as 
causative or complicating factors in humans with CAP.  Novel molecular 
methods have allowed sensitive and rapid detection of several viral pathogens, 
and therefore, in recent years increasing new research information has 
emerged regarding the etiology of CAP and the role of viruses. Co-infections 
with respiratory viruses are currently identified in up to 40% of humans with 
CAP (Camps Serra et al., 2008; Choi et al., 2012; Luyt and Kaiser, 2012; 
Huijskens et al., 2013). Lower respiratory tract samples are considered ideal 
when diagnosing viral infections in humans with CAP, and virus-positive PCR 
in BALF has been shown to be associated with human respiratory symptoms 
(Garbino et al., 2009; Luyt and Kaiser, 2012). 
Huijskens et al. (2014) reported that clinical signs and laboratory findings 
were not useful in the identification of CAP patients with viral co-infections. 
Data concerning the effect of viral co-infections in CAP severity are 
contradictory. Some studies have shown that mixed infections with viruses 
and bacteria induce a more severe clinical disease, whereas others have been 
unable to demonstrate significant differences (Angeles Marcos et al., 2006; 
Jennings et al., 2008; Johnstone et al., 2008; Johansson et al., 2011; Cilloniz 
et al., 2012). 
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2.4.4 VIRAL CO-INFECTIONS IN DOGS WITH BACTERIAL 
PNEUMONIA 
In household dogs, BP is most often caused by opportunistic bacteria 
belonging to the normal oral flora (Thayer and Robinson, 1984; Jameson et 
al., 1995; Wingfield, 1997). The high prevalence of opportunistic infections 
leads to the question of possible predisposing factors. Viral infections have 
generally been considered as a possible predisposing cause in the development 
of BP (Ford, 2009), although few published reports have addressed this 
subject.  
Viral-bacterial co-infections have been almost exclusively described in 
kenneled dogs infected with primary bacterial pathogens known to contribute 
to CIRD (B. bronchiseptica, Mycoplasma spp., and Str. zooepidemicus).  
Isolated reports describe the detection of CIRD viruses in dogs with BP caused 
by opportunistic bacterial infections (Damian et al., 2005; Almes et al., 2010). 
However, very little information is available on household dogs with BP; the 
prevalence of viral co-infections, clinical characteristics, and the effect on 
disease severity have not yet been reported. 
2.5 ACUTE PHASE RESPONSE 
The acute phase response (APR) is a complex nonspecific inflammatory 
response that occurs shortly after any tissue injury. The APR is highly 
nonspecific and may result from a variety of disease processes inducing 
infectious, immune-mediated, neoplastic, and traumatic diseases (Eckersall 
and Bell, 2010). APR is triggered by pro-inflammatory cytokines, mainly 
interleukin (IL) -1, IL-6, and tumor necrosis factor alpha (TNF-?), which are 
produced by neutrophils and monocytes in response to bacterial toxins or 
tissue injury (Petersen et al., 2004). APR is a part of the innate immune system 
and has critical functions in the early stages of infection.  
APR induces changes in blood proteins called acute phase proteins (APPs). 
Some APPs decrease in concentration (so-called negative APPs such as 
albumin and transferrin) and others increase in concentration (so-called 
positive APPs such as C-reactive protein [CRP], serum amyloid A [SAA], 
haptoglobin [Hp], alpha-1-acid glycoprotein, ceruloplasmin, and fibrinogen). 
APPs have several roles, including regulation of immune response, initiation 
and maintenance of inflammation, protection against infection, and repair and 
recovery of damaged tissue (Ceron et al., 2005). 
APPs are mainly produced in the liver. However, there is evidence that 
APPs may be produced also in other tissues and in white blood cells (Ceron et 
al., 2005). It has been postulated that this extrahepatic production of APPs at 
the site of the initial injury may contribute to maintaining homeostasis by 
reducing tissue damage caused by the inflammation (Fournier et al., 2000). 
APR occurs rapidly and may be considered one of the earliest markers of a 
pathologic process. The response patterns of different APPs vary depending 
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on the particular APP and also among species, and they are sub-grouped 
according to their kinetic properties. The major positive APPs, such as CRP 
and SAA in dogs, have low physiological levels, but rise rapidly within hours 
after inflammatory stimulus and normalize quickly when inflammatory 
stimulus ceases (Eckersall and Bell, 2010). Due to these properties, the major 
positive APPs have received the most attention as inflammatory biomarkers. 
The intermediate positive APPs, such as Hp in dogs, show a more delayed rise 
and decline during the APR (Ceron et al., 2005). 
2.5.1 C–REACTIVE PROTEIN (CRP) 
C-reactive protein was identified in humans as early as in the 1930s, when it 
was first discovered in humans with pneumonia caused by Pneumococcus spp. 
(Tillett and Francis, 1930). Later, numerous applications have evolved using 
CRP as a diagnostic, prognostic, and follow-up marker in human medicine. 
Increasing research interest in the 21st century has been directed towards the 
different clinical applications of serum CRP measurement in dogs (Eckersall 
and Bell, 2010). 
CRP structure and kinetics 
Canine CRP resembles the human CRP protein and is a cyclic pentamer with 
five identical non-covalently bound subunits (Caspi et al., 1984). A difference 
between human and canine CRP is the glycosylation of two subunits in canine 
CRP (Caspi et al., 1984), which could explain the difficulties in canine CRP 
measurement when using human antibodies (Ceron et al., 2005).  
CRP concentrations in healthy dogs are generally low and are not affected 
by age or sex (Yamamoto et al., 1994b; Kuribayashi et al., 2003). However, 
elevations of CRP during inflammation in adult animals seem to be more 
pronounced than in very young animals (Hayashi et al., 2001). Serum CRP 
concentrations in dogs do not appear to follow a circadian rhythm, and 
significant day-to-day variation has not been noted (Otabe et al., 1998). 
Physiological elevations in serum CRP have been noted in bitches during 
pregnancy (Kuribayashi et al., 2003), in dogs after road transportation (Fazio 
et al., 2015), and after strenous exercise in racing sledge dogs and hunting dogs 
(Wakshlag et al., 2010; Casella et al., 2013). CRP production is inhibited by 
obesity and insulin resistance, resulting in lower serum CRP concentrations in 
markedly obese animals (Veiga et al., 2008). Glucocorticoid treatment does 
not influence CRP levels in dogs (Martinez-Subiela et al., 2004). Several drugs, 
e.g. angiotensin converting enzyme inhibitors and anti-inflammatory agents, 
lower serum CRP concentrations in humans (Prasad, 2006). 
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CRP as an inflammatory biomarker 
The elevations in serum CRP were first studied after experimentally induced 
inflammation in laboratory dogs (Yamashita et al., 1994; Hayashi et al., 2001) 
and in dogs with surgical trauma (Conner et al., 1988; Yamamoto et al., 1993). 
According to these studies, after the initiation of the inflammatory stimulus, 
there is a lag-phase of approximately four hours before increasing CRP 
concentrations are detected in the circulation (Conner et al., 1988; Higgins et 
al., 2003). Peak concentrations are reached in approximately 24 hours 
(Conner et al., 1988; Yamamoto et al., 1993). 
 Elevated serum CRP concentrations have later been detected in various 
infectious diseases such as bacterial pneumonia (Yamamoto et al., 1994b), 
Bordetella bronchiseptica bronchitis (Yamamoto et al., 1994a), monocytic 
erlichiosis (Mylonakis et al., 2011; Rudoler et al., 2015; Shimada et al., 2002), 
leishmaniosis (Sasanelli et al., 2007, Martinez-Subiela et al., 2003; Martinez-
Subiela et al., 2011), babesiosis (Matijatko et al., 2007; Suzuki et al., 2007), 
esophageal spirocercosis (Mylonakis et al., 2012), heartworm infection 
(Mendez et al., 2015), parvoviral enteritis (Kocaturk et al., 2010), and 
pyometra (Fransson et al., 2004; Dabrowski et al., 2009; Jitpean et al., 2014a). 
Immune-mediated disease processes are also capable of triggering the APR, 
and CRP elevations have been reported in dogs with immune-mediated 
hemolytic anemia (Mitchell et al., 2009), immune-mediated polyarthritis 
(Kjelgaard-Hansen et al., 2006; Ohno et al., 2006), and steroid-responsive 
arteritis meningitis (Bathen-Noethen et al., 2008). Mild to moderate 
elevations in serum CRP have been reported in dogs with congestive heart 
failure due to myxomatous mitral valve disease (Ljungvall et al., 2010; 
Cunningham et al., 2012). 
The magnitude of CRP elevation in neoplastic diseases reflects the amount 
of inflammation and tissue necrosis present, and elevated concentrations of 
APPs have been reported in a variety of malignancies (Tecles et al., 2005; 
Mischke et al., 2007; Planellas et al., 2009; Chase et al., 2012). In dogs with 
lymphoma, serum CRP concentrations decrease after initiation of 
chemotherapy, but this cannot be applied to identify dogs in complete 
remission or dogs with lymphoma relapses during follow-up (Merlo et al., 
2007; Nielsen et al., 2007). A recent study by Alexandrakis et al. (2014) 
showed that an algorithm using serum CRP and Hp was able to identify dogs 
with a lymphoma relapse before the appearance of lymphadenopathy and 
showed prognostic potential during the follow-up period. Chemotherapy itself 
does not affect serum CRP concentrations (Merlo et al., 2007). 
The non-specific nature of the APR hinders the wide use of APPs as 
diagnostic biomarkers. However, it has been shown that serum CRP is useful 
in discriminating disease processes such as pyometra from endometrial 
hyperplasia (Fransson et al., 2004) and steroid-responsive meningitis arteritis 
from other neurological diseases (Bathen-Noethen et al., 2008) as well as in 
identifying early postoperative complications (Dabrowski et al., 2009). 
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The prognostic value of initial serum CRP concentrations has been studied 
in dogs with critical illnesses such as acute abdomen syndrome (Galezowski et 
al., 2010), systemic inflammatory response syndrome and sepsis (Gebhardt et 
al., 2009), acute pacreatitis (Mansfield et al., 2008), and pyometra (Jitpean et 
al., 2014c). These studies all concluded that initial serum CRP concentrations 
were not connected to disease severity or prognosis. Kocaturk et al. (2010; 
2015) reported contradictory findings in puppies with a parvovirus infection, 
where initial serum CRP was associated with disease severity and prognosis. 
This could be explained by secondary bacterial infections and endotoxemia 
serving both as major triggers for APR and as major complicating factors 
leading to a more severe disease in parvoviral enteritis. 
Contrary to the initial CRP concentrations, persistent elevations in serum 
CRP after 48–72 hours of therapy were linked to poor outcome in dogs with 
acute abdomen syndrome (Galezowski et al., 2010), acute pancreatitis 
(Mansfield et al., 2008), and systemic inflammatory response syndrome and 
sepsis (Gebhardt et al., 2009). In addition, in dogs with leishmaniosis and 
immune-mediated polyarthritis an elevation of serum CRP during the follow-
up period preceded a relapse in the clinical disease (Kjelgaard-Hansen et al., 
2006; Sasanelli et al., 2007).  
C-reactive protein in humans with community-acquired pneumonia 
C-reactive protein has been utilized in humans with CAP as a diagnostic, 
prognostic, and follow-up marker for decades. In addition to other diagnostic 
procedures, current human guidelines recommend measuring serum CRP in 
patients suspected with CAP (Lim et al., 2009; Woodhead et al., 2011). 
According to human guidelines, CAP is considered very likely when CRP is > 
100 mg/l in a patient with compatible clinical presentation and unlikely when 
CRP is <20 mg/l and symptoms have lasted more than 24 hours (Woodhead 
et al., 2011). Serum CRP measurement can be applied in humans to distinquish 
bacterial pneumonia from non-bacterial infections and from exacerbations of 
asthma and COPD (Flood et al., 2008; Bafadhel et al., 2011). 
The utility of serum CRP measurement as a follow-up biomarker has been 
studied widely in humans with CAP. Consecutive CRP measurements within 
the first week of CAP were found to be useful in assessing treatment response 
and in identifying patients with a poor response to therapy (Coelho et al., 
2007; Bruns et al., 2008). A failure of serum CRP to decline by day three or 
four after initiation of therapy was connected to a worse outcome (Coelho et 
al., 2007; Moreno et al., 2010). The pattern of CRP reflections during the first 
days of hospitalization is also useful when assessing the treatment response; 
patients with a persistently high serum CRP and those with a biphasic 
response characterized by a later rise in serum CRP after an initial decline had 
a poor prognosis (Moreno et al., 2010; Coelho et al., 2012). Daily CRP 
measurements may allow the early identification of human patients with an 
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inadequate antimicrobial treatment regimen, infectious complications, and a 
risk of deterioration (Coelho et al., 2012). 
Since serum CRP declines rapidly after initiation of successful therapy, it 
has been hypothesized that the normalization of CRP could indicate a suitable 
endpoint for antimicrobial treatment. Ehl et al. (1997) showed that when 
serum CRP was used to individually guide the duration of antibiotic treatment 
in neonatal septicemia, treatment length was significantly reduced without 
increasing relapses. Similar studies using CRP in patients with CAP are 
lacking. Another novel inflammatory biomarker, procalcitonin, has been 
revealed to be a useful biomarker in safely reducing the antibiotic treatment 
length in humans with CAP (Christ-Crain et al., 2006; Schuetz et al., 2009; 
Schuetz et al., 2010; Long et al., 2011). 
2.5.2 SERUM AMYLOID A (SAA) 
Serum amyloid A (SAA) is a major positive APP in dogs. SAA is mainly 
produced in the liver, but local production in inflammed tissue has also been 
demonstrated (Kjelgaard-Hansen et al., 2007). Significantly elevated 
concentrations of SAA have been noted two hours after an experimentally 
induced inflammation (Higgins et al., 2003). Similar to CRP, SAA may be 
elevated after stress or strenous exercise in healthy dogs (Casella et al., 2013; 
Fazio et al., 2015). 
SAA has been studied notably less than CRP in dogs. Similar to CRP, 
elevated SAA concentrations have been observed in dogs with several 
infectious diseases such as pyometra (Jitpean et al., 2014b), babesiosis 
(Matijatko et al., 2007), and monocytic erlichiosis (Mylonakis et al., 2011). 
However, inconsistent elevations were detected in other infectious diseases 
such as leishmaniosis (Martinez-Subiela et al., 2003) and esophageal 
spirocercosis (Mylonakis 2012). Immune-mediated disease may elicit SAA 
elevations as reported in dogs with SRMA (Lowrie et al., 2009). High 
interindividual variation in SAA concentrations in dogs with neoplastic 
diseases has been described (Tecles et al., 2005). SAA was significantly 
elevated in dogs with lymphoma, but did not predict relapse (Merlo et al., 
2008).  
Christensen et al. (2014) compared the applicability of CRP and SAA 
measurement in dogs with systemic inflammation and concluded that both 
biomarkers were sensitive indicators of inflammation. However, SAA showed 
a wider range of concentrations and was therefore considered inferior to CRP 
(Christensen et al., 2014).  
Despite extensive research focused on CRP in human medicine, SAA has 
attracted far less research interest in patients with CAP.  The utility of SAA 
measurement has been evaluated in only a very limited number of studies, and 
SAA measurement is not part of routine clinical practice thus far. CRP and SAA 
are well correlated in humans, and the diagnostic value of CRP and SAA did 
not differ in human patients with systemic bacterial infections (Huttunen et 
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al., 2003; Lannergard et al., 2003). Since SAA elevations are induced also by 
subtle inflammatory stimulii in humans, SAA is considered a more sensitive 
marker of minor inflammatory activity typical for viral and non-invasive 
bacterial infections (Lannergard et al., 2003).  
2.5.3 HAPTOGLOBIN (HP) 
Haptoglobin (Hp) has received the most attention in cattle and sheep as a 
major positive APP and as a useful indicator of infectious diseases (Murata et 
al., 2004). In dogs, Hp is a moderate positive APP (Conner et al., 1988). 
Canine Hp resembles the human Hp, but dogs have only one subtype of Hp, 
compared with humans, who have three subtypes (Ceron et al., 2005). Hp 
binds toxic and pro-inflammatory free hemoglobin in plasma and thereby 
reduces inflammation (Murata et al., 2004). Hp also has multiple 
immunomodulatory effects: an inhibitory effect on granulocyte chemotaxis, 
phagocytosis, and bactericidal activity as well as on mast cell and T-cell 
proliferation (Murata et al., 2004). The glycosylation pattern of Hp varies in 
different diseases and further studies are needed to elucidate the full clinical 
applicability of these changes in differentiating and monitoring different 
pathological processes (Andersson et al., 1998; Andersson and Sevelius, 
2001). 
After an experimentally or surgically induced injury in dogs, elevated Hp 
concentrations were first noted at 24 hours and peak concentrations were 
detected 3-4 days after onset of inflammation (Dabrowski et al., 2007; 
Bayramli and Ulutas, 2008). 
Increases in Hp concentrations have been noted during gestation in dogs 
(Vannucchi et al., 2002). Guillermo Couto et al. (2009) reported that serum 
Hp concentrations in greyhounds were lower than in dogs of other breeds. 
Stress and exercise induce an elevation in serum Hp similiarly as described for 
other positive APPs (Casella et al., 2013; Fazio et al., 2015).  
Significant increases in serum Hp occur during glucocorticoid medications 
and hyperadrenocorticism (Martinez-Subiela et al., 2004; Caldin et al., 2009). 
Studies of the utility of Hp measurements in monitoring treatment response 
in dogs with hyperadrenocorticism concluded that Hp did not provide 
additional information over ACTH stimulation test results (McGrotty et al., 
2005; Arteaga et al., 2010).  
Elevated Hp concentrations have been reported in several infectious 
diseases in dogs such as monocytic erlichiosis (Mylonakis et al., 2011), 
pyometra (Dabrowski et al., 2009) esophageal spirocercosis (Mylonakis et al., 
2012), babesiosis (Matijatko et al., 2007), heartworm infections (Mendez et 
al., 2015), leishmaniasis (Martinez-Subiela et al., 2002), and parvoviral 
enteritis (Kocaturk et al., 2010). Various non-infectious diseases, including 
nasal diseases (Sheahan et al., 2010), immune-mediated polyarthritis 
(Eckersall, 1995), and SRMA (Lowrie et al., 2009), have been shown to elicit 
APR and Hp elevations. Variable Hp elevations have been detected in dogs 
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with neoplastic diseases (Mischke et al., 2007; Planellas et al., 2009; Chase et 
al., 2012).  
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3 AIMS OF THE THESIS 
The objective of this thesis was to study dogs with BP, with special reference 
to the applicability of APPs as diagnostic and follow-up markers, and to 
evaluate the role of viral co-infections in these dogs. Detailed aims were as 
follows: 
 
 
1. To describe the clinical variables, radiographic findings, and serum APP 
concentrations at presentation and during natural course of BP in dogs 
(Studies I and II). 
 
2. To evaluate serum CRP concentrations in dogs with different lung 
diseases and cardiogenic edema and to further assess whether serum 
CRP measurement could be used as a diagnostic biomarker in bacterial 
lung diseases (Study I). 
 
3. To assess the utility of serum CRP measurement in the estimation of 
antimicrobial treatment length (Study II). 
 
4. To investigate the occurrence of viral respiratory infections in 
household dogs diagnosed with BP and to assess the possible 
demographic or clinical variables associated with viral co-infections as 
well as to evaluate the impact of viral co-infections on the clinical 
picture of dogs with BP (Study III). 
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4 MATERIALS AND METHODS 
4.1 STUDY DESIGN 
Studies I and III were conducted as prospective cross-sectional observational 
studies. Study II was conducted as a prospective longitudinal observational 
study.  
Sample size was calculated by power analysis (confidence level 95%, power 
80%) in Study I. A priori sample size calculations were not performed in 
Studies II and III.  
4.2 STUDY POPULATION, DIAGNOSTIC CRITERIA, AND 
CLINICAL EXAMINATIONS 
4.2.1 DOGS WITH BACTERIAL PNEUMONIA (STUDIES I, II, III) 
Bacterial pneumonia was diagnosed in the presence of typical acute signs (at 
least three of the following: fever, lethargy, dyspnea, tachypnea, cough) and 
findings compatible with BP in thoracic radiographs (Dear, 2014; Ford, 2009). 
A bacterial origin was proven by cytological confirmation of bacterial infection 
in respiratory samples (>2 intracellular bacteria/50 oil immersion fields), 
positive bacterial culture (≥103 CFU/ml in airway samples) (Peeters et al., 
2000), or a rapid response to antibiotics and full clinical and radiographic 
normalization with antibiotic treatment. All dogs were followed until full cure, 
natural death, or euthanasia. If a dog died or was euthanized during the study 
period, a post-mortem examination was performed to confirm BP. 
Twenty-six privately owned pet dogs diagnosed with BP at the Veterinary 
Teaching Hospital of the University of Helsinki (VTHH), Finland, were 
prospectively recruited during 2011-2013. The dogs participated in different 
studies as follows: Study I, 22 dogs; Study II, 19 dogs; and Study III, 20 dogs.  
The dog population comprised 12 females and 14 males (mean age 3.6 years 
± STD 3.1, range 0.5-10.8 years), and the following breeds were represented: 
mixed breed (n=3), Great Dane (n=3), Irish wolfhound (n=2), Labrador 
retriever (n=2), and German shepherd, Doberman pinscher, Chinese crested 
dog, Weimaraner, West Highland white terrier, Pharaoh hound, Bullmastiff, 
Spanish water dog, Borzoi, Schnauzer, Scottish deer hound, Lagotto 
romagnolo, Wire haired dachshund, Beagle, Dutch shepherd, and Rottweiler 
(one of each).  
Respiratory samples were collected for bacterial culture (26/26) and 
cytological analysis (24/26). Sampling methods included BAL (13/26), TTW 
(10/26), TTA (2/26), and a fresh sputum sample (1/26). The diagnostic 
evaluation included also history and physical examination (26/26), 
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hematology (26/26), serum biochemistry (24/26), thoracic radiographs 
(26/26), arterial blood gas analysis (25/26), fecal examination (19/26), and 
blood culture (12/26).  
4.2.2 DOGS WITH BACTERIAL TRACHEOBRONCHITIS (STUDIES I, III) 
The diagnosis of bacterial tracheobronchitis (BTB) was based on clinical signs 
(acute or chronic cough), findings in thoracic radiographs (absence of alveolar 
density), and a positive bacterial culture (>103 CFU/ml) in BALF (Study I). The 
diagnosis of prolonged tracheobronchitis caused by B. bronchiseptica (BBTB) 
was based on clinical signs (cough lasting for more than 30 days) and a positive 
bacterial culture of B. bronchiseptica (>103 CFU/ml) in BALF (Study III). 
Twenty privately owned pet dogs diagnosed with BTB at the VTHH were 
recruited. Samples were collected during 2007-2012; 17 dogs were included in 
Study I and 13 in Study III. Bronchoscopy and BAL were performed on all 
dogs, and other concurrent lung pathology was excluded. Additional 
diagnostic examinations included thoracic radiographs (20/20), hematology 
(17/20), arterial blood gas analysis (17/20), and fecal examination (15/20).   
Twelve males and 8 females were included (mean age 1.0 years ± STD 1.6, 
range 0.3-7.9 years). The dogs represented various breeds: Boxer (n=3), 
Australian terrier (n=2), Shetland sheepdog (n=2), mixed breed (n=2), and 
Bull terrier, Miniature bull terrier, English bulldog, Irish wolfhound, Papillon, 
German shepherd, Labrador retriever, Yorkshire terrier, and Toy poodle (one 
of each).  
4.2.3 DOGS WITH CHRONIC BRONCHITIS (STUDY I) 
The diagnosis of chronic bronchitis (CB) was based on the presence of chronic 
cough (>2 months of duration), typical bronchoscopic findings (e.g. increased 
mucus production, irregular bronchial mucosa, bronchomalacia or 
bronchiectasia) and the exclusion of other causes capable of causing the signs. 
Twenty dogs diagnosed with CB at the VTHH during 2007-2012 were 
included in the study. In addition to bronchoscopy and BAL (20/20), other 
clinical examinations comprised hematology (19/20), serum biochemistry 
(20/20), arterial blood gas analysis (20/20), thoracic radiographs (20/20), 
thoracic high-resolution computed tomography (HRCT) (5/20), 
echocardiography (8/20), and fecal analysis (16/20). Dogs with both 
inflammatory (increased total cell count and predominance of non-degenerate 
neutrophils in BALF) and non-inflammatory cytologic findings were included 
in the CB group. 
The group comprised 13 males and 7 females, and their mean age was 9.3 
years (STD 4.0, range 2.2-14.5 years). The following breeds were represented: 
Shetland sheepdog (n=4), Bichon frise (n=3), mixed breed (n=3), Smooth fox 
terrier (n=2) and Labrador retriever, Australian shepherd, Griffon bruxellois, 
Toy poodle, Tibetian spaniel, and Chinese crested dog (one of each).  
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4.2.4 DOGS WITH EOSINOPHILIC BRONCHOPNEUMOPATHY (STUDY 
I) 
The diagnosis of idiopathic eosinophilic bronchopneumopathy (EBP) was 
based on respiratory signs and the detection of >20% eosinophil count in 
BALF in the absence of bacterial growth or intracellular bacteria in BALF. 
Pulmonary parasites were excluded with fecal analysis in all dogs. 
Ten privately owned dogs diagnosed with EBP at the VTHH were recruited 
during 2006-2013. Additionally, banked frozen (-80°C) serum samples 
collected from 10 privately owned dogs participating in a previously published 
study describing EBP (Rajamaki et al., 2002) were included in the group. 
Bronchoscopy and BAL were performed on all dogs. Clinical examinations 
included also hematology (20/20), serum biochemistry (20/20), thoracic 
radiographs (20/20), thoracic HRCT (8/20), echocardiography (6/20), and 
arterial blood gas analysis (18/20). 
The group of dogs comprised 5 males and 15 females, and their mean age 
was 4.2 years (STD 2.8, range 0.8-8.5 years). The following breeds were 
represented: mixed breed (n=3), Siberian husky (n=2), Labrador retriever 
(n=2), Finnish lapphund (n=2), and Australian shepherd, Small 
münsterländer, Jack Russell terrier, Australian terrier, Bichon frise, 
Doberman pinscher, German shepherd, Golden retriever, Wire haired 
dachshund, Lapponian herder, and Basset hound (one of each).  
4.2.5 DOGS WITH CANINE IDIOPATHIC PULMONARY FIBROSIS 
(STUDY I) 
The diagnosis of canine idiopathic pulmonary fibrosis (CIPF) was based on 
typical respiratory signs and clinical findings as well as BALF cytology and 
thoracic HRCT findings or a post-mortem pathology confirmation. Twelve 
West Highland White terriers (mean age 12.1 years ± STD 1.8, range 10.2-16.3 
years) diagnosed with CIPF at the VTHH were recruited during 2007-2012. 
The following diagnostic procedures were performed: BALF cytology and 
bacterial culture (12/12), thoracic radiographs (12/12), thoracic HRCT (10/12), 
and post-mortem pathology confirmation (9/12). Additional diagnostics 
included hematology (12/12), echocardiography (11/12), serum biochemistry 
(12/12), arterial blood gas analysis (11/12), and fecal analysis (12/12).  
4.2.6 DOGS WITH CARDIOGENIC PULMONARY EDEMA (STUDY I) 
The diagnosis of cardiogenic pulmonary edema (CPE) was made in the 
presence of typical respiratory signs (cough, tachypnea, or dyspnea), 
interstitial or alveolar infiltration in thoracic radiographs, and confirmed heart 
disease by echocardiography. 
Fifteen dogs diagnosed with CPE at the VTHH were recruited during 2011-
2013. Thoracic radiographs were obtained (15/15) and echocardiography was 
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performed on all dogs by one of the authors (M.M. Rajamäki). Additional 
diagnostics included serum biochemistry (14/15) and hematology (7/15). 
Various breeds were represented as follows: Bichon havanese (n=2), mixed 
breed (n=2), and Pyrenean shepherd, Irish wolfhound, Kerry blue terrier, 
Bretone, Cavalier King Charles spaniel, Norfolk terrier, Bichon frise, Papillon, 
Kleinspitz, Labrador retriever, and Great dane (one of each). The group 
comprised 8 males and 7 females (mean age 10.7 years ± STD 2.8, range 4.4-
14.6 years). 
4.2.7 HEALTHY CONTROL DOGS (STUDIES I, II) 
Altogether 93 privately owned healthy blood donor dogs were recruited as 
controls for serum APP measurements during 2011-2014. Of the dogs, 72 were 
included in Study I and 64 in Study II. These healthy dogs did not have any 
history or clinical signs suggestive of illness and had normal hematology and 
serum biochemistry.  
The group generally comprised young (mean age 3.6 years ± STD 1.3, range 
1.6-6.8 years) large breed dogs (mean weight 38.1 kg ± STD 9.7 kg). Forty-
seven females and 46 males were included, and the following breeds were 
represented: German shepherd (n=15), mixed breed (n=13), Labrador 
retriever (n=13), Hovawart (n=7), Rottweiler (n=4), Rough collie (n=4), 
Golden retriever (n=4), Great dane (n=3), Doberman pinscher (n=3), Belgian 
shepherd malinois (n=2), Giant schnauzer (n=2), Gordon setter (n=2), White 
shepherd (n=2), Bullmastiff (n=2), Leonberger (n=2), Dalmatian (n=2), 
Rhodesian ridgeback (n=2), and Black Russian terrier, Alaskan malamute, 
Galgo Español, Curly coated retriever, American akita, Borzoi, Bernese 
mountain dog, Pyrenese mastiff, Tibetan mastiff, Maremmano-abruzzese, 
Greyhound, Australian shepherd, and Flat coated retriever (one of each). 
4.2.8 EXCLUSION CRITERIA (STUDIES I-III) 
In Studies I and II, where the APR was assessed, other factors possibly 
affecting APP concentrations needed to be taken into account. Therefore, dogs 
with other concurrent infectious, inflammatory, or neoplastic diseases were 
excluded from these studies. Pregnant or lactating bitches and puppies <3 
months of age were also excluded (Kuribayashi et al., 2003). Because 
corticosteroids affect Hp concentrations (Harvey and West, 1987; Martinez-
Subiela et al., 2004), dogs with excess endogenous corticosteroids or 
corticosteroid medication <4 weeks prior to study inclusion were excluded 
from the Hp measurements in Study III. Dogs with CB, EBP, CIPF, or CPE as 
well as healthy controls were excluded if they had received antimicrobial 
treatment <7 days prior to study inclusion. 
In Study III, the prevalence of CIRD pathogens in household dogs was 
assessed, and therefore all dogs living in or recently (<4 weeks ago) exposed 
to environments with high infection pressure (e.g. boarding kennels, rescue 
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shelters) were excluded. Since recent vaccinations can cause false-positive 
PCR results (Ruch-Gallie et al., 2016), dogs that had been vaccinated against 
CDV, CAV-2, CPIV, or Bordetella bronchiseptica <4 weeks prior to inclusion 
in the study were excluded from Study III.  
4.3 ETHICAL APPROVAL OF STUDY PROTOCOLS 
The study protocols were approved by the Ethics Committee for Animal 
Experimentation at the University of Helsinki, Finland. Owners of the 
diseased dogs provided a written informed consent for participation.  
The use of leftover serum samples for research purposes was approved by 
the owners of healthy blood donor dogs. 
4.4 CLINICOPATHOLOGICAL EXAMINATIONS 
In all dogs, history was revised and a thorough general examination was 
performed with a specific focus on the respiratory tract. All dogs were 
examined initially at presentation to VTHH and thereafter daily during 
hospitalization. Additionally, 17 dogs surviving to hospital discharge in Study 
II were examined on control visits every 7-10 days during antimicrobial 
treatment and 2 weeks after the antimicrobial treatment had ceased. 
4.4.1 ANALYSIS OF BLOOD AND FECAL SAMPLES 
Blood samples were collected from the cephalic or jugular vein in all dogs and 
placed in EDTA tubes for hematology analysis and in plain blood collection 
tubes for serum biochemistry analyses. Samples were analyzed without delay 
after blood collection. Hematology analysis was performed using an 
automated hematology analyzer (Advia 2120i, Siemens AG, Munchen, 
Germany) and leukocyte differential count was calculated manually. Serum 
biochemistry was analyzed with an automated clinical chemistry analyzer 
(Konelab 30i, Thermo Scientific, Vantaa, Finland). 
Arterial blood samples were collected from the femoral artery or the dorsal 
metatarsal artery from non-sedated dogs breathing room air. Samples were 
analyzed immediately after sampling with a blood gas analyzer (ABL800 Flex 
Analyzer, Radiometer Medical ApS, Brønshøj, Denmark) at 37°C. Partial 
pressures of arterial oxygen (PaO2) and carbon dioxide (PaCO2) as well as 
alveolar-arterial oxygen gradient (A-aO2), pH, bicarbonate, and acid-base 
excess were recorded. 
Coagulation parameters of prothrombin time (PT) and activated partial 
thromboplastin time (aPTT) were evaluated using commercial canine test kits 
(Thrombotest, Nycomed Pharma, Asker, Norway and DG-APTT Synth Kit, 
Diagnostic Grifols S.A., Barcelona, Spain). 
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Three fecal samples were collected by the owners and examined for 
parasites with MgSO4 flotation and Baermann’s sedimentation methods. 
4.4.2 DIAGNOSTIC IMAGING 
Thoracic radiographs (a minimum of a single laterolateral and a dorsoventral 
or ventrodorsal view) were obtained upon presentation in all dogs with 
respiratory and cardiac diseases. In 17 dogs with BP participating in Study II, 
thoracic radiographs were obtained also on control visits. Thoracic 
radiographs in dogs with BP were assessed blinded from the patient data by 
one of the authors (A.K. Lappalainen). Thoracic radiographs in dogs with other 
respiratory and cardiac diseases were assessed by hospital veterinarians from 
the diagnostic imaging team at VTHH. 
High-resolution computed tomography (HRCT) was performed under 
general anesthesia with a helical dual slice scanner (Somatom Emotion Duo, 
Siemens AG, Munchen, Germany). Images were viewed by a veterinary 
radiologist (A.K. Lappalainen). 
Echocardiography (Philips iE33, Royal Philips, Amsterdam, Netherlands) 
was performed by one of the authors (M.M. Rajamäki).  
4.4.3 RESPIRATORY SAMPLING 
Bronchoscopy and bronchoalveolar lavage 
Bronchoscopy was performed with a 4.9 mm flexible endoscope (Olympus 
GIF-N180, Olympus Medical Systems Europa GmbH, Hamburg, Germany). 
Dogs were preoxygenated for 5-10 minutes prior to the procedure and they 
received supplemental oxygen via an intratracheally placed oxygen catheter 
during the procedure. Individually tailored premedications were used in each 
dog, including intramuscular or intravenous administration of 
dexmedetomidine (Dexdomitor, Orion Pharma, Espoo, Finland), butophanol 
(Butordol, Intervet, Boxmeer, Netherlands), or midazolam (Midazolam 
Accord, Accord Healthcare Ltd., Middlesex, UK), or a combination of the 
aforementioned. Anesthesia was induced and maintained with intravenous 
propofol (PropoVet, Abbot Logistics B.V., Breda, Netherlands) in all dogs.  
Trachea and all lung lobes were systematically evaluated and changes, such 
as tracheal collapse, bronchial mucosal irregularity, bronchomalasia, 
bronchiectasis, erythema, secretions, or other changes, were documented. 
Two separate lung lobes were lavaged with sterile warm (37°C) saline solution. 
A weight-adjusted fluid amount was used in each lung lobe (2 ml/kg divided 
into two aliquots) in all clinically stable dogs. In dogs with BP, one affected 
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lung lobe was lavaged and an aliquot of 0.5-1 ml/kg was initially used and 
repeated only if sufficient sample was not retrieved with the first aliquot.  
Transtracheal wash 
When general anesthesia was considered unsafe due to severe BP, respiratory 
samples were retrieved using TTW.  
The dog was restrained in either standing position or lying in ventral 
recumbency. If needed, premedication with 0.1-0.2 mg/kg butorphanol 
(Butordol, Intervet, Boxmeer, Netherlands) was administered intravenously. 
Additional oxygen was delivered through a nasal oxygen catheter during the 
procedure. Hair was clipped over the ventral neck and the skin was aseptically 
prepared using a surgical scrub. 2% lidocain (Lidocain, Orion Oy, Espoo, 
Finland) was used for local anesthesia approximately 10 minutes prior to the 
procedure. A 14G introduction catheter (Mila Trans-Tracheal Wash Kit, Mila 
International Inc., Erlanger, Kentucky, USA) was placed through the 
cricothyroid ligament into the trachea. The needle was removed and a 16G 
wash catheter was introduced through the introduction catheter into the distal 
trachea. A warm 0.9% saline solution was used to flush the trachea in 5-10 ml 
aliquots until sufficient sample was retrieved. A maximum wash fluid volume 
of 1 ml/kg was not exceeded.  
Transthoracic aspirate biopsy and fresh sputum sample 
Transthoracic aspirate biopsy was used as a sampling method for cytology and 
bacterial culture in one dog too small (5.2 kg) for TTW sampling and unable 
to tolerate general anesthesia and in one dog with a focal lung lesion.  
Dogs were positioned either in ventral or lateral recumbency. Hair was 
clipped and 95% alcohol was applied on the skin. A suitable lung lesion was 
identified with ultrasonography and sampling was performed under 
ultrasonographic guidance using a 23G hypodermic needle.  
A fresh sputum sample was aseptically collected for cytology and bacterial 
culture in one dog with severe hypoxia and a very productive BP.  
4.4.4 RESPIRATORY CYTOLOGY  
BALF and TTW samples were filtered through a single layer of cotton gauze 
prior to analysis. The total cell count was manually calculated using trypan 
blue stained cells (Trypan Blue Solution 0.4%, Sigma-Aldrich, St. Louis, 
Missouri, USA) and a Bürker counting chamber (Brand, Wertheim, Germany). 
A differential cell count was calculated manually (300 cells) after 
cytocentrifugation (Cytospin4, Thermo Scientific, Vantaa, Finland) and May-
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Grünwald Giemsa (MGG) staining. The remaining BALF and TTW samples 
were frozen (-80°C) and later used for PCR analysis (Study III).  
Gram stain was performed on a cytocentrifuged sample and examined for 
the presence of bacteria. When two or more intracellular bacteria were 
detected per 50 oil immersion fields, the examination was considered 
indicative of a bacterial infection (Peeters et al., 2000).  
A smear was produced from TTA samples and from the fresh sputum 
sample and stained with MGG. The cytology was assessed under light 
microscopy and the main cell types as well as the presence of intracellular 
bacteria were recorded. 
4.4.5 BACTERIAL CULTURE 
Semi-quantitative aerobic bacterial cultures were performed on all respiratory 
samples immediately after sampling. In addition to aerobic bacterial cultures, 
anaerobic, Mycoplasma spp., and enrichment cultures were performed on 
dogs with BP.  
For aerobic bacterial cultures, a volume of 10 μl of the specimen was 
streaked onto Tryptone Soy Agar with Sheep Blood (Oxoid Limited, 
Hampshire, UK) and onto Chocolate Agar with Vitox (Oxoid Limited, 
Hampshire, UK). Blood and chocolate agars were incubated at 35°C in 5% CO2 
atmosphere for 7 days and were evaluated daily to detect growth. Anaerobic 
cultures (Fastidious Anaerobe Agar with Horse Blood, Oxoid Limited, 
Hampshire, UK) were incubated under anaerobic conditions at 35°C for 7 days 
and were evaluated every second day. Enrichment tubes (Fastidious Anaerobe 
broth, Oxoid Limited, Hampshire, UK) were incubated at 35°C for 7 days and 
inspected daily. If cloudiness was detected, a swab from the enrichment tube 
was streaked onto the above-mentioned agars and only a qualitative result was 
given. 
Species identification was performed by conventional methods. 
Antimicrobial susceptibility testing was carried out following standardized 
methods (disk diffusion or E-test). Bacterial counts were quantified by 
calculating the colonies on a plate and multiplying the number of colonies by 
the dilution factor. The limit of detection was 1.0 x 102 CFU/ml. Bacterial 
growth was considered significant when >103 CFU/ml was detected (Peeters 
et al., 2000).  
Samples for Mycoplasma spp. culture were transferred to transport 
medium (Copan Universal Transport Medium, UTM-RT System, Copan, Italy) 
and shipped to a national reference laboratory (Evira, Kuopio, Finland) for 
specific Mycoplasma spp. culture.  
Blood cultures were aseptically collected from the jugular vein into a 
vacuum culture medium (BactAlert FA and BactAlert SN Culture Mediums, 
Biomerieux Inc., USA) and incubated in an automated microbial detection 
system (BactAlert 3D60, Biomerieux Inc., USA). 
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4.5 ACUTE PHASE PROTEIN MEASUREMENTS 
4.5.1 C-REACTIVE PROTEIN (STUDIES I, II, III) 
Serum CRP was analyzed using a magnetic two-sided immunoassay 
(LifeAssays Canine CRP Point of Care Analyzer, LifeAssays AB, Lund, Sweden) 
previously validated for use in dogs (Ibraimi et al., 2013). 
The assay reagent utilizes conjugated superparamagnetic nanoparticles 
and silica particles, both of which carry covalently bound polyclonal anti-
canine CRP antibodies. The reaction is initiated by introducing the sample into 
the reagent. Anti-canine CRP microparticles bond with serum CRP antigen 
and form a sandwich complex. The sandwich complexes sediment to the 
bottom of the reagent vial, separating bound complexes from unbound 
microparticles. The subsequent increase in magnetic permeability in the pellet 
caused by the bound magnetic particles is measured. 
Serum samples for CRP measurement were either immediately analyzed or 
stored frozen at -80°C until analyzed. Results below the detection limit for the 
assay (<10 mg/L) were set to equal 5 mg/L, and results beyond the upper 
detection limit for the assay (>210 mg/L) were set to equal 211 mg/L. 
A CRP ratio (CRP concentrations at 24 h, 48 h, and 72 h divided by the 
initial concentration), describing the decline in CRP during early recovery, was 
calculated after initiation of therapy in dogs with samples available for the 
time-point in question (Study III). 
 
4.5.2 SERUM AMYLOID A (STUDY II) 
Serum samples for SAA analysis were frozen after collection, stored at -80°C 
and shipped in dry ice to an external laboratory (Department of Veterinary and 
Clinical Sciences, University of Copenhagen, Denmark) for analysis.  
SAA was analyzed using an automated (Advia 1800, Siemens AG, 
Munchen, Germany) latex agglutination turbidimetric immunoassay (SAA-1, 
Eiken Chemical Company, Tokyo, Japan) previously validated for dogs 
(Christensen et al., 2012). The assay is based on monoclonal anti-human SAA 
antibodies. 
4.5.3 HAPTOGLOBIN MEASUREMENT (STUDY II) 
Serum samples for Hp analysis were frozen after collection and stored at -80°C 
until analysis. Hp was analyzed using a commercial assay kit (Phase 
Haptoglobin Assay Kit TP-801, Tridelta Development Ltd., County Kildare, 
Ireland) validated for dogs (Eckersall et al., 1999), and the analysis was run 
with Konelab Pro Selective Chemistry Analyzer (Thermo Scientific, Vantaa, 
Finland).  
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The assay applies a colorimetric method in the quantification of Hp. Briefly, 
the test utilizes the following principle: Free hemoglobin has peroxidase 
activity, which is inhibited at a low pH. When there is Hp present in the 
sample, Hp combines with free hemoglobin. At a low pH, the peroxidase 
activity of bound hemoglobin is preserved and is directly proportional to the 
amount of Hp present. The assay uses a peroxidase chromogen as a reagent, 
and the increase in absorbance at 600 nm for the reagent is measured.  Hp 
concentrations in unknown samples are derived by comparison with a 
standard curve. 
Three dogs in Study II had received exogenous corticosteroids prior to 
inclusion and one dog was diagnosed with Cushing’s disease after the study 
period. These dogs were excluded from Hp measurements.  
4.6 ANTIMICROBIAL TREATMENT LENGTH (STUDY II) 
The dogs recruited at the beginning of Study II received antimicrobial 
treatment following conventional recommendations (Dear, 2014; Ford, 2009). 
These dogs were treated for 3–6 weeks or 1–2 weeks beyond the resolution of 
alveolar density on the thoracic radiographs. Antimicrobial treatment of dogs 
entering the study in 2012 was discontinued 5–7 days after serum CRP 
returned to normal limits (< 25 mg/L). The CRP-guided approach was applied 
only when owners agreed to its use.   
4.7 PCR ANALYSIS OF RESPIRATORY PATHOGENS 
(STUDY III) 
BALF and TTW samples were shipped to external laboratories for PCR 
analysis for respiratory pathogens. CPIV, CAV-2, CHV, CIV, canine distemper 
virus (CDV), and CRCoV as well as Mycoplasma spp. were analyzed by a real-
time PCR analysis at a commercial reference laboratory (IDEXX GmbH, 
Germany). CnPnV was analyzed by RT-PCR at an academic facility (Animal 
Health Diagnostic Center, College of Veterinary Medicine, Cornell University, 
Ithaca, USA).  
4.8 STATISTICAL METHODS 
Statistical analyses were performed using commercial statistical software 
(PASW Statistics 18, SPSS Inc., USA; SAS System for Windows, version 9.3, 
USA; R version 3.2.3., The R Foundation for Statistical Computing, Austria). 
Normality of the data was explored using the Shapiro-Wilk test of normality 
and Normal Q-Q plots. P-values <0.05 were considered statistically 
significant.  
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The differences in CRP between disease groups in Study I were evaluated 
with analysis of variance (ANOVA) models. Together with disease variables, 
age, gender, and weight were used as fixed effects in the model to control for 
possible confounding effects. CRP did not follow the normal distribution in 
several disease groups, and therefore, the analysis was performed for Rank-
transformed data. Sidak’s correction was used in pair-wise comparisons to 
control for the family-wise error rate. 
The differences between groups in Studies II and III were evaluated with 
the independent-samples Student’s t-test (normally distributed variables) and 
the Mann-Whitney U-test (non-normally distributed variables). Bonferroni 
correction (Study II) was used in pair-wise comparisons. 
Correlations between variables were assessed with Spearman’s correlation 
coefficients (Studies I, II, and III).  
In Study I, the effect of antibiotics use prior to entering the study was 
evaluated with ANOVA models for dogs with bacterial respiratory disease 
(BTB and BP). The fitted model included fixed effects for disease and use of 
antibiotics. 
In Study III, the mean curves were calculated with the random effects 
ANOVA. For CRP and SAA, a logarithmic transformation was computed to 
normalize the distribution and the fitted values estimated from the models 
were transformed back to the original scale to represent the geometric mean 
of the response in time. For Hp and PaO2, the absolute values were used as 
the response, and the mean curves were computed directly from the fitted 
values. As explanatory variables, the models included the fixed effects of 
group, day, and the two-way interaction of group*day and the random effects 
of dog and dog*day. 
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5 RESULTS 
5.1 CLINICAL FINDINGS IN BACTERIAL PNEUMONIA 
5.1.1 HISTORY AND CLINICAL EXAMINATION 
All dogs with BP were presented to the VTHH as acute emergency cases of 
varying severity. The median length of clinical signs prior to presentation was 
1.0 days (IQR 1.0-4.0 days, range 0.5-7.0 days). Of 26 dogs, 4 had a history of 
BP within the last 12 months.   
The owners reported the following complaints upon admission to the 
VTHH: lethargy (25/26), fever (22/26), respiratory distress (6/26), tachypnea 
(18/26), and cough (23/26). 
Four dogs had received corticosteroids (oral prednisolone 2/4, single oral 
dose of hydrocortisone 1/4, and inhaled fluticazone 1/4) and 13/26 dogs had 
received antibiotics prior to presentation.  
Clinical examination findings comprised lethargy in 20/26, tachypnea 
(respiratory rate >30/min) in 22/26, expiratory dyspnea in 6/26, cough in 
19/26 (spontaneous 15/26 and after tracheal provocation 4/26), abnormal 
lung auscultation findings in 19/26, fever (>39.3°C) in 14/26, bilateral nasal 
discharge in 4/26, decreased capillary refill time (≤ 1 second) in 3/26, and joint 
pain in 2/26 dogs.  
5.1.2 HEMATOLOGY, COAGULATION, AND FECAL ANALYSIS 
Blood samples for hematology analysis were obtained in all dogs with BP, 
and the results were the following: leukocytosis (>17.4 x109 /l in 6/26 dogs, 
leukopenia (<5.4 x109 /L) in 3/26, neutrophilia (>13.8 x109/l) in 7/26, left 
shift (band neutrophils >0.1 x109/l) in 17/26, monocytosis (>1.1 x109/l) in 
10/26, lymphopenia (<1.0 x109/l) in 13/26, and eosinopenia (<0.1 x109/l) in 
12/26 dogs. Detailed hematology results are presented in Table 6.  
PT and aPTT were measured in 8/26 dogs on 15 different occasions either 
at presentation or during hospitalization. PT was normal in all measurements. 
Mildly prolonged aPTT was noted in 3/8 dogs.  
Fecal analysis was available for 19 dogs, and all samples were negative for 
lung and gastrointestinal parasites.  
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5.1.3 ARTERIAL BLOOD GAS ANALYSIS 
Arterial blood samples were obtained in 25/26 dogs with BP at presentation. 
Results are shown in Table 6. Arterial oxygenation was followed during the 
disease and recovery period in 19 dogs with BP (Study II), and the results are 
displayed in Figure 1.   
 
 
 
 
A         B 
Figure 1 Partial pressure of arterial oxygen (PaO2) in dogs with bacterial pneumonia (BP) 
(n=19) during the disease and follow-up period. Each line shows results of a 
single dog. A shows dogs with a less severe BP requiring < 2 days of 
hospitalization and B dogs with a more severe BP requiring >2 days of 
hospitalization. 
 
5.1.4 THORACIC IMAGING 
Radiographic findings in dogs with BP (n=26) at presentation to the VTHH 
are shown in Table 3.  
The resolution of radiographic changes was followed during the recovery 
period in 17 dogs participating in Study II. The alveolar pattern found in 13/17 
dogs was resolved in a median of 10 days (IQR 8–15 days), and 9/13 dogs had 
cleared alveolar infiltrates by day 10.  
At a follow-up visit 2 weeks after discontinuation of antibiotics, 15/17 dogs 
still presented a mild to moderate bronchial, bronchointerstitial, or interstitial 
pattern. 
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Table 3 Thoracic radiographic findings in dogs with bacterial pneumonia (n=26). 
Main radiographic pattern Number of dogs Location 
 
Alveolar, single lobe 6/26 Right cranial lobe 1/6 
Right middle lobe 1/6  
Right caudal lobe 1/6 
Left cranial cranial lobe 1/6 
Left caudal cranial lobe1/6 
Alveolar, multiple lobes 15/26 Right cranial lobe 10/12 
Right middle lobe 9/12 
Right caudal lobe 1/12 
Left cranial cranial lobe 9/12 
Left caudal cranial lobe 7/12 
Left caudal lobe 2/12 
Accessory lobe 1/12 
  Patchy alveolar 3/12 
Bronchointerstitial 
 
5/26  
5.1.5 BRONCHOSCOPY FINDINGS 
Bronchoscopy and BAL were performed on 13 dogs with BP. This group of dogs 
was generally less severely affected with BP. Anesthetic complications did not 
occur during the procedure and none of the dogs deteriorated after BAL. 
Changes in the trachea were noted in 5/13 dogs; these included purulent 
secretions 3/5, grade I tracheal collapse in 1/5, and an orifice in the tracheal 
bifurcation in 1/5 (this dog was later diagnosed with a tracheoesophageal 
fistula). Abundant purulent secretions were found in the bronchi of 11/13 dogs. 
Secretions were detected in the same lung lobes as the alveolar radiographic 
pattern, but also in other lung lobes with a bronchointestitial or interstitial 
radiographic pattern in 5/13 dogs. Other bronchoscopy findings included mild 
to moderate bronchial mucosal hyperemia in 7/13, mild bronchial mucosal 
irregularity in 2/13, bronchiectasis in 2/13, and mild bronchomalacia in 1/13 
dogs. 
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5.1.6 RESPIRATORY CYTOLOGY 
BALF and TTW cytology findings in BP and a comparison between the two 
sampling methods are presented in Table 4. Cytology analysis was available in 
13/13 BALF samples and in 8/10 TTW samples. 
Cytology in TTA (n=2) and fresh sputum samples (n=1) consisted mostly of 
numerous neutrophils, and intracellular bacteria were detected in all cases.  
 
 
 
 
Table 4 Comparison between bronchoalveolar lavage fluid (BALF) and transtracheal 
wash (TTW) cytology results in dogs with bacterial pneumonia.  
 BALF 
n = 13 
TTW 
n = 8 
p-value 
 
 Median (IQR) Median (IQR)  
Total cell count (109/l) 1.4 (0.1–10.6) 4.7 (0.2–31.7) 0.536 
Neutrophils (%) 66.1 (7.7–95.9) 65.2 (12.0–90.2) 0.185 
Eosinophils (%) 0.4 (0.0–9.0) 1.0 (0.1–3.5) 0.860 
Mast cells (%) 0.0 (0.0–1.8) 0.0 (0.0–0.0) 0.697 
Lymphocytes (%) 5.0 (0.7–16.6) 4.7 (0.4–20.4) 0.238 
Macrophages (%) 23.7 (3.7–57.9) 22.1 (8.2–57.6) 0.089 
Epithelial cells (%) 0.0 (0.0–0.0) 0.0 (0.0–0.7) 0.016 
Basophils (%) 0.0 (0.0–0.0) 0.0 (0.0–0.0)  
Plasma cells (%) 0.0 (0.0–0.0) 0.0 (0.0–0.0)  
 
 
 
 
 
 
 
 
 
 
 
 63 
5.1.7 MICROBIOLOGICAL FINDINGS 
Aerobic bacterial culture was performed on all dogs with BP. Additionally, 
anaerobic bacterial culture and culture with an enrichment broth were 
performed on 19/26 dogs.  
A single species of bacteria was detected in 18/22 dogs with bacterial 
growth, and two species were detected in four dogs. In three dogs, 
simultaneous growth of Pasteurella spp. and Mycoplasma spp. was detected, 
and one dog had simultaneous E. coli and Arcanobacter spp. growth. Four 
dogs did not have bacterial growth in respiratory samples. Anaerobic bacterial 
growth was not detected in any of the dogs. A summary of the culture results 
is provided in Table 5. 
Mycoplasma cultures were sent to an external laboratory for 15/26 dogs 
and were positive for Mycoplasma spp. in 4/15 dogs. As mentioned above, 
three of these dogs had a concomitant growth of Pasteurella spp.. For one dog, 
only Mycoplasma spp. were detected. The presence of Mycoplasma spp. was 
additionally examined using a PCR method in 20 dogs with BP (Study III). 
Mycoplasma spp. were detected with PCR in 8/20 dogs: Four of these dogs 
had positive Mycoplasma culture results, two had negative culture results, and 
two did not have Mycoplasma culture performed. When dogs with positive 
Mycoplasma PCR or culture results (n=8) were compared with dogs with 
negative results (n=12), the length of hospitalization, age or weight of the dogs, 
hematology and arterial blood gas analysis results, and the differential cell 
count in respiratory samples did not differ significantly among groups. The 
total cell count in respiratory samples (BALF n=13, TTW n=7) was 
significantly higher (median 13.9, IQR 3.5-34.0 cells x109/l) in dogs with 
Mycoplasma spp. detected than in Mycoplasma-negative dogs (median 0.3, 
IQR 0.1-1.9 cells x109/l, p=0.025). In Mycoplasma-positive dogs, 2/8 samples 
were collected using TTW and in Mycoplasma-negative dogs 5/12 samples.  
Blood cultures were performed on 12/26 dogs and were positive for 4/12 
dogs. In two dogs with BP caused by E. coli, blood culture was consistent with 
respiratory culture findings. In two dogs, Staphylococcus spp. were detected 
in blood culture.  
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Table 5 Aerobic, anaerobic and Mycoplasma culture results in dogs with bacterial 
pneumonia (n=26).  
 Dogs with significant 
bacterial growth in 
primary culture (n=15) 
Dogs with bacterial 
growth after 
enrichment (n=7) 
Dogs with no 
bacterial growth 
(n=4) 
BALF (n=13) 8/13 4/13 1/13 
TTW (n=10) 4/10 3/10 2/10 
Antimicrobial therapy 
prior to sampling 
(n=13) 
7/15 4/7 2/4 
Culture results Pasteurella sp. 4/15  
Escherichia. coli 3/15 
E. coli, Arcanobacter sp. 
1/15 
Streptococcus sp. 3/15  
Mycoplasma sp. 3/15  
Hemophilus sp. 1/15 
Actinomyces sp. 1/15  
Nocardiopsis sp. 1/15 
Actinomyces sp. 2/7 
 Streptococcus sp. 2/7 
Pasteurella sp. 2/7 
Haemophilus sp. 1/7 
Mycoplasma sp. 1/7 
 
Intracellular bacteria  9/12 1/5 0/2 
BALF=Bronchoalveolar lavage fluid, TTW=Transtracheal wash 
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5.1.8 FACTORS CONNECTED TO DISEASE SEVERITY 
Disease severity varied in dogs with BP, from dogs managed solely with peroral 
antibiotics at home to dogs dying of severe pneumonia despite hospitalization 
and intensive care. Of 26 dogs, 20 required hospitalization. All hospitalized 
dogs received supplemental oxygen using either a nasal oxygen catheter or an 
oxygen collar, additionally severely affected small and medium-sized dogs 
were placed in an oxygen chamber. None of the dogs were managed with 
mechanical ventilation. The median length of hospitalization was 1.8 days 
(IQR 0.8-4.1, range 0-14 days).  
The correlation between demographic and clinical variables at presentation 
and length of hospitalization was assessed, and the results are shown in Table 
6. Additionally, the number of affected lung lobes (lung lobes with an alveolar 
pattern) was significantly correlated with the length of hospitalization 
(r=0.683, p<0.001). 
Of the 26 dogs, 24 survived to discharge. One dog died due to severe BP 
and one was euthanized due to refractory BP caused by multiresistant E. coli. 
Financial factors did not influence treatment decisions in this study; none of 
the owners refused hospitalization or selected euthanasia for financial 
reasons. 
Dogs with BP caused by E. coli (n=4) were hospitalized significantly 
(p=0.026) longer (median 4.5 days, range 4.0-5.5 days) than dogs with BP 
caused by other bacteria (median 1.5 days, range 0-14 days). Three dogs with 
BP caused by E. coli showed clinical findings suggestive of septic shock 
(decreased capillary refill time ≤ 1 second, fever ≥ 40°C) at presentation to the 
VTHH. Mildly prolonged aPTT was noted in 3/4 dogs with E. coli as a 
causative agent. Of four dogs with BP caused by E. coli, one died and another 
was euthanized during hospitalization.  
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Table 6 Demographic data, clinical findings, and hematology, arterial blood gas analysis, 
and respiratory cytology results in dogs with bacterial pneumonia (n=26) and the 
correlation of these variables with the length of hospitalization. 
 Dogs with bacterial 
pneumonia 
Correlation with length of 
hospitalization 
 Mean ± SD or median (IQR) p-value R 
Weight, kg 32.0 ± 20.4 0.752 0.065 
Body temperature, °C 39.4 ± 0.9 0.529 0.129 
Respiratory rate, /min 55.5 ± 20.8 0.068 0.379 
Heart rate, /min 103 ± 20 0.847 0.041 
Arterial paO2, mmHg  75.3 ± 11.3 0.003 -0.562 
Arterial paCO2, mmHg  30.1 ± 3.4 0.850 -0.041 
Alveolar-arterial O2 gradient 39.3 ± 12.3 0.013 0.491 
Age, years 2.6 (0.8-5.8) 0.467 0.149 
Duration of clinical signs, days 1.0 (1.0-4.0) 0.426 -0.163 
Serum urea, mmol/l 4.1 ± 1.2 0.310 -0.227 
Serum glucose, mmol/l 5.8 ± 0.9 0.620 0.102 
Blood leukocyte count, 109/l 12.6 (8.5-18.2) 0.018 -0.461 
  Segmented neutrophils 9.8 (5.8-14.4) 0.015 -0.472 
  Band neutrophils 0.5 (0.04-1.4) 0.091 0.339 
  Lymphocytes 1.0 (0.4-1.7) 0.061 -0.372 
  Eosinophils 0.1 (0.0-0.5) 0.201 -0.259 
  Monocytes 0.7 (0.3-1.5) 0.159 -0.285 
  Basophils 0.0 (0.0-0.0) 0.512 -0.135 
BALF total cell count, 109/l 1.4, 0.2-15.2 (0.1-45.2) 0.241 0.275 
BALF Neutrophils, % 66.1, 12.2-95.4 (4.7-99.9) 0.014 0.517 
BALF Eosinophils, % 0.7, 0.0-4.0 (0.0-24.7) 0.014 -0.526 
BALF Mast cells, % 0.0, 0.0-0.0 (0.0-4.4) 0.004 -0.607 
BALF Lymphocytes, % 4.7, 0.4-8.9 (0.0-29.4) 0.011 -0.543 
BALF Macrophages, % 22.1, 3.9-53.7 (1.1-66.7) 0.006 -0.577 
BALF Epithelial cells, % 0.0, 0.0-0.4 (0.0-7.2) 0.976 -0.007 
BALF=Bronchoalveolar lavage fluid 
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Table 7 Comparison of demographic data, clinical findings, and hematology, arterial 
blood gas analysis, and respiratory cytology results between dogs with a less 
severe bacterial pneumonia requiring < 2 days of hospitalization (lsBP, n=10) 
and a more severe bacterial pneumonia requiring > 2 days of hospitalization 
(msBP, n=9). 
 Dogs with  lsBP 
Mean ± SD or 
Median (IQR) 
Dogs with msBP 
Mean ± SD or 
Median (IQR) 
 
p–value 
Duration of symptoms, days 3.0 (1.0–7.0) 1.5 (1.0–3.5) 0.315 
Body weight, kg 36.5 ± 17.5  33.6 ± 24.6 0.764 
Body temperature, °C 39.3± 0.9 39.6 ± 0.9 0.419 
Respiratory rate,  / min 43 ± 22 61 ± 17 0.064 
Leukocyte count, 109/l 20.2 ± 16.3 12.1 ± 6.5 0.183 
Segmented neutrophil count, 109/l 15.9 ± 14.2 9.3 ± 5.5 0.234 
Band neutrophil count, 109/l 0.1 (0.0–0.7) 1.4 (0.3–2.8) 0.035 
Lymphocyte count, 109/l 2.2 ± 1.6 0.5 ± 0.3 0.009 
Eosinophil count, 109/l 0.4 ± 0.4 0.1 ± 0.2 0.078 
Monocyte count, 109/l 0.7 (0.4–2.3) 0.4 (0.2–1.4) 0.278 
Basophil count, 109/l 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.720 
Arterial PaO2, mmHg 84.6 ± 6.8 69.0 ± 9.8 0.001 
Arterial PaCO2, mmHg 30.8 (27.0–31.1) 28.8 (28.4–32.2) 0.842 
Alveolar-arterial O2 gradient 30.8 ± 10.8 46.5 ± 9.2 0.003 
pH 7.41 ± 0.02 7.41 ± 0.6 0.893 
HCO3, mmol/L 18.2 ±1.7 18.7 ± 3.4 0.669 
Base excess, mEq/L -4.6 ± 1.3 -4.3 ± 3.9 0.833 
Respiratory sample cytology (n=15)    
 Neutrophils, % 14.7 (5.3–76.2) 96.4 (46.8–97.8) 0.019 
 Eosinophils, % 3.7 (0.6–13.2) 0.0 (0.0–0.4) 0.008 
 Mast cells, % 0.0 (0.0–2.7) 0.0 (0.0–0.0) 0.254 
 Lymphocytes, % 14.6 ±11.2 2.3 ±3.1 0.008 
 Macrophages, % 42.9 ± 22.9 17.2 ± 27.6 0.077 
 Epithelial cells, % 0.0 (0.0–0.2) 0.0 (0.0–8.5) 1.000 
 
 68 
5.1.9 VIRAL CO-INFECTIONS IN BACTERAL PNEUMONIA (STUDY III) 
The presence of respiratory viruses in BALF or TTW samples was assessed 
using PCR in 20/26 dogs with BP (Study III). CPIV was detected in 7/20 (35%, 
95% confidence interval 14–56%) and CRCoV in 1/20 (5%, 95% confidence 
interval 0–15%) dogs. CAV-2, CHV, CIV, CDV, or CnPnV was not detected in 
any of the samples.  
Detailed demographic data, clinical findings, and hematology, arterial 
blood gas analysis, and respiratory cytology results as well as a comparison 
between dogs with positive and negative PCR results are presented in Table 8. 
Briefly, dogs with viral co-infections were significantly heavier (p=0.037) than 
dogs with negative PCR results. Dogs in the PCR-positive group were also 
younger than dogs with negative PCR results, although this finding did not 
reach statistical significance (p=0.057). Duration of clinical signs or 
hospitalization, body temperature, respiratory rate, serum CRP, hematology, 
arterial blood gas analysis, and BALF and TTW cytology results did not differ 
significantly between dogs with and without a viral co-infection. 
5.1.10 ETIOLOGY OF BACTERIAL PNEUMONIA 
Other concomitant respiratory diseases or infections possibly predisposing to 
BP were identified in 14/26 dogs (CIRD viruses 8/26, chronic bronchitis 2/26, 
aspiration 1/26, oral abscess 1/26, and tracheoesophageal fistula 1/26). A 
summary of the dogs with possible predisposing factors is presented in Table 
9. In addition, a possible breed-related predisposition to BP was suspected in 
one Irish wolfhound and in one Scottish deerhound with a history of previous 
BP (Clercx et al., 2003). In these dogs, BP reccurred 3-6 months after the study 
period.  
Laryngeal examination was not consistently performed on dogs with BP, 
and therefore, aspiration etiology could not be fully excluded. Except for the 
one dog with a gastric foreign body and vomiting, none of the dogs with BP 
had a history of vomiting, regurgitation, recent anesthesia, or signs compatible 
with laryngeal paralysis. 
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Table 8 Demographic data, clinical findings, and hematology, arterial blood gas analysis, 
and respiratory cytology results in dogs with bacterial pneumonia, comparing 
dogs with positive (n=8) and negative (n=12) respiratory virus PCR results.  
 Negative  virus PCR Positive  virus PCR p-value 
 Mean ± SD or median (IQR) Mean ± SD or median (IQR)  
Weight, kg 25.0 ± 16.4 41.7 ± 15.7 0.037 
Body temperature, ºC 39.6 ± 0.9 39.2 ± 0.8 0.31 
Respiratory rate, /min 59 ± 21 45 ± 20 0.15 
Arterial PaO2, mmHg  74.9 ± 11.1 79.1 ± 14.1 0.49 
Arterial PaCO2, mmHg  29.3 ± 3.9 30.9 ± 1.1 0.19 
Alveolar-arterial O2 gradient 41.3 ± 11.8 33.5 ± 14.4 0.23 
Age, years 5.8 (1.3-8.4) 0.9 (0.7-1.4) 0.057 
Duration of clinical signs, days 1.0 (1-3.5) 3.0 (1.0-5.3) 0.48 
Duration of hospitalization, days 1.8 (0.0-4.8) 1.0 (0.3-1.5) 0.43 
Serum C-reactive protein, mg/L 140 (84-192) 63 (52-178) 0.98 
Blood leukocyte count, 109/l 14.6 (12.5-22.0) 10.6 (7.4-22.9) 0.34 
  Segmented neutrophils 11.7 (9.1-15.6) 7.8 (5.2-17.5) 0.27 
  Band neutrophils 0.5 (0.08-2.0) 0.3 (0.0-0.9) 0.48 
  Lymphocytes 0.7 (0.4-1.7) 1.5 (0.4-3.6) 0.52 
  Eosinophils 0.3 (0.0-0.6) 0.2 (0.0-0.6) 0.91 
  Monocytes 1.0 (0.3-1.7) 0.7 (0.5-1.5) 0.97 
  Basophils 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.68 
Respiratory cytology  
(BALF n=13, TTW n=7) 
   
  Total cell count, 109/l 1.4 (0.1-10.6) 4.7 (0.2-31.7) 0.57 
Neutrophils, % 66.1 (7.7-95.9) 65.2 (12.0-90.2) 0.91 
Eosinophils, % 0.4 (0.0-9.0) 1.0 (0.1-3.5) 0.62 
Mast cells, % 0.0 (0.0-1.8) 0.0 (0.0-0.0) 0.57 
Lymphocytes, % 5.0 (0.7-16.6) 4.7 (0.4-20.4) 1.00 
Macrophages, % 23.7 (3.7-57.9) 22.1 (8.2—57.6) 1.00 
 Epithelial cells, % 0.0 (0.0-0.0) 0.0 (0.0-0.7) 0.57 
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Table 9 Summary of possible predisposing factors in dogs with bacterial pneumonia. 
Breed 
 
Sex Age Possible predisposing 
factor 
Labrador retriever Female 0.9 year CPiV infection 
German shepherd Male 5.6 years CPiV infection 
Dutch shepherd Female 0.9 year CPiV infection 
Labrador retriever Male 1.5 years CPiV infection 
Bullmastiff Female 1.3 years CPiV infection 
Rottweiler Male 0.7 year CPiV infection 
Great Dane Male 0.7 year CPiV infection 
Great Dane Male 0.8 year CRCoV infection 
Wirehaired Dachshund Female 6.7 years Chronic bronchitis 
West Highland White Terrier Female 9.0 years Chronic bronchitis 
Beagle Male 5.7 years Aspiration  
Schnauzer Male 6.3 years Oral abscess 
Spanish water dog Female 0.6 year Tracheoesophageal fistula 
Great Dane Female 5.6 years Cushing’s disease 
 
5.2 CLINICAL FINDINGS IN OTHER DISEASE GROUPS 
Respiratory rate, body temperature, hematology, and arterial blood gas 
analysis results for dogs with BTB, CB, EBP, CIPF, and CPE are shown in Table 
8. Bronchoscopy and BAL was performed in all dogs with BTB, CB, EBP, and 
CIPF, and cytology results are also presented in Table 10. All dogs with CB, 
EBP, and CIPF had negative bacterial culture findings.  
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Table 10 Clinical findings, hematology, arterial blood gas analysis, and respiratory 
cytology results in dogs with bacterial tracheobronchitis (BTB), chronic bronchitis 
(CB), eosinophilic bronchopneumopathy (EBP), canine idiopathic pulmonary 
fibrosis (CIPF), and cardiogenic pulmonary edema (CPE). 
  
BTB 
n= 20 
 
CB 
n= 20 
 
EBP 
n=20 
 
CIPF 
n=12 
 
CPE 
n=15 
 Mean ± SD or Median (IQR) 
 Body temperature, ºC 38.9 ± 0.5 38.7 ± 0.7 38.7 ± 0.5 38.5 ± 0.4 38.2 ± 0.6 
Respiratory rate, /min 39.9 ± 12.6 45.1 ± 23.7 24.8 ± 6.9 57.6 ± 35.1 61.,0 ± 22.9 
Arterial paO2, mmHg  88.0 ± 12.3 81.3 ± 12.8 91.7 ± 11.1 63.0 ± 8.7  
Arterial paCO2, mmHg  35.3 ± 6.4 30.1 ± 4.7 31.8 ± 3.8 30.5 ± 4.1  
Alveolar-arterial O2 
gradient 
24.8 ± 9.8 34.9 ± 12.8 26.8 ± 8.1 51.3 ± 10.2  
Blood leukocyte count, 
109/l 
13.3 (10.8-17.4) 9.0 (7.1-10.4) 10.0 (8.9-12.4) 9.7 (7.4-11.9) 10.1 (6.0-12.3) 
 Segmented neutrophils 8.1 (6.7-12.2) 6.4 (4.9-9.7) 6.3 (5.4-7.9) 7.5 (5.2-9.4) 4.0 (3.8-7.5) 
Band neutrophils 0 (0-0.1) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Lymphocytes 2.8 (2.3-4.2) 1.6 (1.2-3.3) 1.9 (1.3-2.5) 1.4 (1.1-1.5) 1.5 (1.4-1.7) 
Eosinophils 0.4 (0.2-0.7) 0.3 (0.2-0.5) 1.2 (0.8-2.1) 0.3(0.1-0.6) 0.35 (0.2-0.7) 
Monocytes 1.0 (0.6-1.2) 0.7 (0.4-1.1) 0.5 (0.4-0.7) 0.5 (0.3-1.0) 0.5 (0.2-1.0) 
 Basophils 0 (0-0.03) 0.02 (0-0.05) 0.15 (0-0.3) 0 (0-0.01) 0.01 (0-0.01) 
BALF total cell count, 
109/l 
0.6 (0.2-1.2) 0.23 (0.1-0.4) 0.99 (0.4-1.7) 1.09 (0.72-1.59)  
BALF neutrophils, % 11.6 (3.9-46.2) 5.7 (2.7-14.4) 5.2 (2.4-10.1) 6.5 (4.2-13.0)  
BALF eosinophils, % 2.2 (0.4-3.9) 1.7(0.4-6.0) 50.7 (41.2-65.5) 0.2 (0-0.6)  
BALF mast cells, % 0.0 (0-0.4) 1.4 (0.7-3.0) 0.9 (0-1.9) 0.7 (0.2-1.0)  
BALF lymphocytes, % 11.9 (5.9-22.1) 12.0 (6.4-17.4) 7.9 (3.7-14.2) 6.0 (4.4-6.7)  
BALF macrophages, % 59.7 (40.2-68.7) 75.0 (54.0-85.0) 29.7 (16.2-37.2) 85,1 (77.6-89.4)  
BALF epithelial cells, % 0 (0-2.9) 0 (0-0.4) 0.4 (0-1.2) 0 (0-0)  
BALF basophils, % 0 (0-0-) 0 (0-0) 0 (0-0) 0 (0-0)  
BALF plasma cells, % 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)  
 
 
 72 
Dogs with bacterial tracheobronchitis (Studies I, III) 
All dogs with BTB were clinically stable and were presented to the VTHH for 
subacute or chronic cough. The median duration of clinical signs was 62 days 
(IQR 30-120 days, range 7-360 days). Of the 20 dogs, seven had received 
peroral antibiotics <7 days prior to study inclusion. Radiographic findings 
included bronchial or bronchointestial pattern in 17/20 dogs. Thoracic 
radiographs were interpreted as normal in 3/20 dogs. Alveolar pattern was not 
detected in any of the dogs. Fecal samples were available for 15/20 dogs and 
were negative for lung worms in all dogs. One dog had intestinal parasites 
(Coccidia spp.). 
Significant bacterial growth in aerobic cultures (>103 CFU/ml) was 
detected in all dogs. Microbiological findings comprised B. bronchiseptica in 
15/20, Pasteurella spp. in 2/20, E. coli in 1/20, Haemophilus spp. in 1/20, and 
Klebsiella pneumoniae and Streptococcus canis in 1/20 dogs.  
Respiratory viruses (CPiV, CAV-2, CHV, CRCoV, CIV, CDV, and CnPnV) 
were not detected with PCR methods in dogs (n=13) with BBTB (Study III). 
The presence of Mycoplasma spp. infection was evaluated with a culture 
method in 4/13 dogs and with a PCR method in 13/13 dogs with BBTB 
participating in Study III. Culture was positive in 2/4 dogs and PCR was 
positive in 4/13 dogs. PCR was positive in the two dogs with positive culture 
findings. PCR was also positive in one dog with negative culture findings and 
in another dog lacking a Mycoplasma culture. 
Dogs with chronic bronchitis (Study I) 
All 20 dogs with CB were clinically stable and had chronic cough as their main 
sign. The median duration of clinical signs was 6 months (IQR 4-12 months, 
range 2-36 months). Four dogs were treated with glucocorticoids at the time 
of presentation to the VTHH. Changes in thoracic radiographs were noted in 
18/20 dogs, and the most commonly reported abnormality was moderate to 
severe bronchial or bronchointerstitial pattern. In all dogs, visible changes 
were evident in bronchoscopy and included bronchial wall irregularity 
(17/20), bronchomalasia (18/20), increased amount of mucus (5/20), and 
bronchiectasia (7/20). None of the dogs had significant bacterial growth or 
eosinophilia in BALF. Fecal analysis was available for 16/20 dogs and was 
negative in all cases.  
Dogs with eosinophilic bronchopneumopathy (Study I) 
All dogs with EBP suffered from chronic cough. In addition, exercise 
intolerance of varying degree was commonly noted. The median duration of 
clinical signs was 5 months (IQR 2.6-6.8 months, range 1.5-24 months). The 
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radiographic changes most commonly detected were moderate to severe 
bronchial or bronchointerstitial pattern. Solely interstitial pattern was 
detected in 2/20 dogs, and alveolar pattern was detected in 2/20 dogs. 
Thoracic radiographs were interpreted as normal in two dogs. BALF 
eosinophilia (>20%) was present in all dogs, and fecal analysis was negative 
for lung worms in all dogs. In two dogs, intestinal parasites were detected 
(Ancylostoma caninum in one dog and Coccidia spp. in the other). 
Dogs with canine idiopathic pulmonary fibrosis (Study I) 
The dogs with CIPF presented most commonly with either cough, exercise 
intolerance, or panting, or a combination of these. Detailed clinical, 
radiographic, and HRCT findings are previously reported in a study describing 
CIPF in West Highland white terriers (Heikkilä et al., 2011). Fecal analysis was 
negative in all dogs.  
Dogs with cardiogenic pulmonary edema (Study I) 
Dogs with cardiogenic pulmonary edema were presented to the VTHH with 
acute or subacute onset of cough, tachypnea, or respiratory distress of varying 
severity. The median duration of clinical signs was 5 days (IQR 2-14 days, 
range 1-30 days), and the clinical signs reported on admission to the VTHH 
comprised cough (12/15), tachypnea (11/15), respiratory distress (3/15), and 
collapse (1/15). In thoracic radiographs, an alveolar pattern was detected in 
11/15 dogs and a severe intersititial or bronchointerstitial pattern in 4/15 dogs. 
Echocardiography was performed on all dogs to confirm the underlying 
cardiac disease. Of the 15 dogs, 11 were diagnosed with myxomatous mitral 
valve disease and 4 with dilated cardiomyopathy.  
5.3 ACUTE PHASE PROTEINS IN BACTERIAL 
PNEUMONIA 
5.3.1 EFFECT OF POSSIBLE CONFOUNDING FACTORS IN SERUM C-
REACTIVE PROTEIN (STUDY I) 
Age (p=0.15), sex (p=0.37), or body weight (p=0.15) did not affect serum CRP 
concentrations in the entire material (dogs with BP, BTB, CB, EBP, CIPF, or 
CPE and healthy dogs). Prior antibiotic treatment did not affect serum CRP in 
dogs with bacterial diseases (BTB and BP; p=0.58). The duration of clinical 
signs did not affect CRP concentration in dogs with BP (p=0.17), BTB (p=0.61), 
or CPE (p=0.15). 
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5.3.2 CORRELATIONS BETWEEN ACUTE PHASE PROTEINS AND 
CLINICAL VARIABLES 
Significant correlations between clinical variables and serum CRP are 
presented in Table 11.  
 
Table 11 Significant correlations between serum CRP and clinical findings, hematology, 
arterial blood gas analysis, and respiratory cytology results in the entire patient 
group (all dogs), dogs with bacterial tracheobronchitis (BTB), dogs with chronic 
bronchitis (CB), dogs with bacterial pneumonia (BP), and dogs with canine 
idiopathic pulmonary fibrosis (CIPF) in Study I.  
 Patient group Correlation to serum CRP 
  p-value R 
Body temperature, ºC All dogs 0.020 0.25 
Respiratory rate (/min) All dogs 0.003 0.33 
Arterial paCO2 mmHg  Dogs with BP 0.022 -0.50 
Blood leukocyte count 109/l All dogs 0.018 0.23 
 Blood segmented neutrophils 109/l All dogs 0.0007 0.34 
 Band band neutrophils 109/l All dogs <0.0001 0.64 
 Dogs with BTB 0.012 0.59 
 Blood lymphocytes 109/l Dogs with CB 0.033 -0.49 
 Blood eosinophils 109/l All dogs <0.0001 -0.48 
 Dogs with CB 0.0091 -0.58 
 Blood basophils 109/l All dogs 0.0002 -0.36 
BALF total cell count (109/l)    
BALF Neutrophils (%) Dogs with BTB 0.015 0.58 
BALF Eosinophils (%) All dogs <0.0001 -0.48 
 Dogs with CB 0.0091 -0.58 
 Dogs with CIPF 0.0058 -0.74 
BALF Mast cells (%) All dogs 0.012 -0.27 
BALF Macrophages (%) Dogs with CB 0.0016 0.67 
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The serum concentrations of positive APPs at presentation to the VTHH 
were significantly correlated with each other in Study III: CRP and SAA 
(r=0.60, p=0.015), CRP and Hp (r=0.61, p=0.010), and SAA and Hp (r=0.85, 
P<0.001). Significant correlations between positive APPs and serum albumin 
(a negative APP) did not arise in all comparisons: SAA was significantly 
negatively correlated with albumin (r=-0.53, P=0.035), but CRP (r=-0.22, 
p=0.40) and Hp (r=-0.15, p=0.58) were not.   
5.3.3 SERUM C-REACTIVE PROTEIN AS A DIAGNOSTIC BIOMARKER 
(STUDY I) 
Serum C-reactive protein concentrations in dogs with various respiratory 
diseases (BP, BTB, CB, EBP, CIPF), in dogs with CPE, and in healthy dogs are 
presented in Figure 2. 
 
 
 
Figure 2 Serum C-reactive protein (CRP) concentrations in dogs with bacterial 
tracheobronchitis (BTB, n=17), chronic bronchitis (CB, n=20), eosinophilic 
bronchopneumopathy (EBP, n=20), idiopathic pulmonary fibrosis (CIPF, n=12), 
cardiogenic pulmonary edema (CPE, n=15), bacterial pneumonia (BP, n=22), 
and healthy controls (n=72) in Study I.   
*) Dogs with BP had significantly higher CRP concentrations (median 121 mg/l, 
interquartile range 68-178 mg/l) than dogs with BTB (23, 15-38, p=0.0003), CB 
(13, 8-14 , p<0.0001), EBP (5, 5-15, p<0.0001), CIPF (17, 10-20, p<0.0001) , or 
CPE (19, 13-32, p <0.0001),  and healthy controls (14, 8-20, p<0.0001). 
**) Dogs with BTB had significantly higher CRP concentrations than dogs with 
CB (p=0.0010) or EBP (p<0.0001) or healthy controls (p=0.029). 
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5.3.4 ACUTE PHASE PROTEINS AS PROGNOSTIC MARKERS (STUDY 
II) 
Serum APP concentrations in dogs with BP at presentation to the VTHH and 
the comparison between dogs with a less severe BP (lsBP) requiring <2 days 
of hospitalization and dogs with a more severe BP (msBP) requiring >2 days 
of hospitalization are shown in Figure 3.  
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Figure 3 Serum acute phase protein concentrations at presentation in healthy dogs 
(n=64), dogs with a less severe bacterial pneumonia (lsBP) requiring < 2 days of 
hospitalization (n=10) and in dogs with a more severe bacterial pneumonia 
(msBP) requiring >2 days of hospitalization (n=9) in Study II.   
A) C-reactive protein (CRP): Healthy dogs, median 11.0 mg/l, interquartile range 
5.0–16.0, n=47; lsBP, 101.5, 62.3–182.5, n=10; msBP, 142.0, 98.0–211.0, n=9.  
B) Serum amyloid A (SAA): Healthy dogs, median 3.9 mg/l, interquartile range 
1.7–9.1, n=64; lsBP, 1048.2, 236.3–1522.2, n=9; msBP, 1336.9, 778.3–3650.0, 
n=7. 
C) Haptoglobin (Hp): Healthy dogs, median 0.5 mg/ml, interquartile range 0.2–
1.7, n=64, in lsBP, 3.7, 2.5–7.3, n=8; msBP, 6.9, 2.7–13.3, n=6.  
D) Albumin: Healthy dogs, median 31.4 g/l, interquartile range 29.4–33.0, n=64; 
lsBP, 30.6, 27.3–32.2, n=9; msBP, 27.3, 24.2–31.9, n=8. 
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Serum APPs at presentation were not significantly correlated with variables 
reflecting disease severity such as duration of hospitalization (CRP r=0.36, 
p=0.24; SAA r=0.462, p=0.072; Hp r=0.305, p=0.235), arterial PaO2 (CRP 
r=0.353, p=0.138; SAA r=-0.450, p=0.080; Hp r=-0.48, p=0.052), or A-aO2 
(CRP r=0.35, p=0.14; SAA r=0.42, p=0.11; Hp r=0.42, p=0.090).   
CRP ratio (CRP concentrations at 24 hours, 48 hours, and 72 hours divided 
by the initial concentration) was calculated for hospitalized patients at 24 
hours (median 1.0, interquartile range [IQR] 0.6-2.2, n=11), 48 hours (median 
0.95, IQR 0.8-1.1, n=8), and 72 hours (median 1.0, IQR 0.8-1.2, n=5). CRP 
continued to rise in the first 24 hours in 5/11 dogs. CRP ratios after 24 hours 
(r=0.35, p=0.30), 48 hours (r=0.46, p=0.25), and 72 hours (r=-0.15, p=0.81) 
were not correlated with duration of hospitalization. 
5.3.5 ACUTE PHASE PROTEINS AS MARKERS OF TREATMENT 
RESPONSE (STUDY II) 
Serum CRP, SAA, Hp, and albumin concentrations during hospitalization and 
the recovery period are shown in Figure 4. 
5.3.6 SERUM CRP IN AIDING THE ESTIMATION OF ANTIMICROBIAL 
TREATMENT LENGTH (STUDY II) 
Seventeen of 19 dogs survived to hospital discharge in Study II. In nine of 
these dogs, CRP was not used for determining the length of antimicrobial 
treatment, and dogs received antibiotics according to conventional 
recommendations (median length of treatment 35 days, IQR 29–48 days, 
range 26-88 days). Of these nine dogs, six had lsBP and three had msBP. 
Bacteria susceptible to the initially chosen antimicrobials was detected in 
15/17 dogs. In two dogs, bacterial growth was not detected and therefore 
antimicrobial susceptibility could not be addressed. Of these two dogs, one was 
treated according to conventional recommendations and one was treated CRP-
guided. 
Antimicrobial treatment was discontinued 5–7 days after CRP 
normalization in 8/17 dogs (median length of treatment 21 days, IQR 19–29 
days, range 18-65 days). lsBP was observed in 4/8 and msBP in 4/8 dogs. CRP-
guided treatment was significantly shorter (p=0.015) than conventional 
treatment.  
One dog treated conventionally had a relapse of BP after antibiotic 
discontinuation, and Cushing’s disease was later found as a predisposing 
factor. The other 16 dogs did not show clinical signs or findings suggestive of 
BP relapse at follow-up visits occurring 2 weeks after antibiotic 
discontinuation or during follow-up phone calls at 4–8 weeks after the follow-
up visit.  
 
 
 78 
A            B 
A              B 
A               B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Serum C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp) 
concentrations in dogs with bacterial pneumonia (BP) (n=19) during the disease 
and follow-up period. Each line shows results of a single dog. A presents dogs 
with a less severe BP requiring < 2 days of hospitalization and B dogs with a 
more severe BP requiring >2 days of hospitalization. 
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6 DISCUSSION 
Although BP is a common and well-known disease entity in small animal 
medicine, it has attracted limited research interest, especially during the last 
decades. Consequently, the clinical and diagnostic findings in BP have been 
reported almost solely in retrospective case series and follow-up studies have 
not been published. This thesis summary reports clinical and diagnostic 
findings as well as serum acute-phase protein concentrations in 26 
prospectively recruited dogs diagnosed with BP and follow-up findings during 
the disease and recovery periods in 19 of these dogs. 
6.1 BACTERIAL PNEUMONIA – NEW INSIGHTS INTO AN 
OLD DISEASE? 
6.1.1 CLINICOPATHOLOGICAL FINDINGS 
Our findings confirmed the previous conclusion (Thayer and Robinson, 1984) 
that dogs with BP are mainly large breed dogs; in our study, the mean weight 
was 32 kg and 65% of dogs weighed >20 kg. We found a slight male 
predominance (54% male, 46% female), as also reported previously in BP 
(Thayer and Robinson, 1984) and in AP (Kogan et al., 2008b; Tart et al., 2010). 
However, the male predominance found in our study and in the previous 
studies is relatively small, and therefore, the clinical relevance is questionable.  
Clinical signs and physical examination findings in our study were in line 
with those reported elsewhere (Radhakrishnan et al., 2007; Thayer and 
Robinson, 1984). An acute onset of lethargy, cough, tachypnea, and 
respiratory distress were the most common complaints on admission. In 
addition to these, abnormal lung auscultation findings were commonly noted 
in physical examination. Fever was found in 73% of dogs, which is more often 
than in earlier studies, which reported fever in less than half of dogs 
(Radhakrishnan et al., 2007; Thayer and Robinson, 1984). We also noted 
clinical findings suggestive of polyarthritis in a small group of dogs with BP. 
This had not been reported before, but is not unexpected in dogs with BP; 
secondary immune-mediated polyarthritis may be triggered by a bacterial 
respiratory infection (Johnson and Mackin, 2012). According to both our 
study and previous research (Kogan et al., 2008a; Radhakrishnan et al., 2007; 
Thayer and Robinson, 1984), typical clinical signs and general examination 
findings (cough, tachypnea, respiratory distress, fever, and abnormal 
auscultation) are not consistently present in all dogs with BP and the lack of a 
single finding, e.g. fever or cough, cannot rule out the diagnosis of BP. 
However, it has been shown in humans that CAP can be dependably ruled out 
when all vital signs are normal (Lim et al., 2009). While this has not been 
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addressed in dogs, it is likely that similarly normal vital signs could rule out 
BP in dogs as well.  
The numbers of blood leukocytes are largely affected by extravasation into 
pulmonary parenchyma during acute bacterial infection, and therefore, 
hematology appears to be rather insensitive as a diagnostic test in dogs with 
BP. Leukocytosis and neutrophilia were detected in a minority of dogs (23% 
and 27% of dogs, respectively) also in our study. Concordant with previous 
studies, left shift was the most commonly encountered hematological 
abnormality, occurring in 65% of our dogs (Thayer and Robinson, 1984).  
Hypoxia of varying severity was commonly detected in dogs with BP. PaO2 
results in our study (mean 75 mmHg) are slightly higher than previously 
reported (mean 61 mmHg) by Wingfield et al. (1997). Evidently, the most 
important feature that affects the PaO2 results is the patient group chosen. In 
our study, also less severely affected dogs, treated with peroral antibiotics 
without hospitalization, were included. In addition to the patient 
characteristics in these two studies, the results may be affected by altitude: 
Wingfield (1997) reported findings in Fort Collins, Colorado, at an altitude of 
1500 meters above sea level, whereas our dogs lived in Southern Finland at an 
altitude of 50 m or less above sea level.  
As expected, initial arterial PaO2 reflected disease severity and was 
significantly correlated with length of hospitalization. Retention of PaCO2 was 
not encountered, and hypocapnea, most likely due to increased respiratory 
rate, was commonly detected. This is in accordance with Wingfield (1997), who 
reported lower PaCO2 in dogs with pneumonia than in healthy dogs.  
We reported serial arterial blood gas measurements during disease and the 
recovery period in 19 dogs with BP (Figure 1). PaO2 returned to normal in less 
severely affected dogs relatively rapidly, and an increase in PaO2 was noted 
often already during the first two days. In more severely affected dogs, PaO2 
often declined during the first days of hospitalization, and normalization of 
arterial PaO2 required a markedly longer time. A consistent decline in arterial 
PaO2 during hospitalization was found in both dogs that did not survive. 
Considering these findings, a decline in PaO2 during the first days of BP could 
be indicative of a more severe course of the disease. 
Arterial PaO2 had returned to normal reference levels in most dogs by the 
last control visit 2 weeks after the antimicrobial treatment had ceased. In two 
dogs with a severe BP requiring extended hospitalization, PaO2 rose slowly 
during the follow-up period, but was slightly below the normal reference range 
at the last control visit and returned to normal at a later time-point. Based on 
this, our results suggest that a slow normalization of PaO2 should not raise 
concerns, assuming other clinical findings and the general condition of the dog 
are improving. 
Lung worms were not detected in any of the dogs with BP in our study. This 
was expected since BP has not been described as a feature in parasitic lung 
infections (Sherding, 2004). Additionally the low prevalence of parasitic lung 
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infections in Finland may have affected the results (personal communication, 
M.M. Rajamäki). 
6.1.2 RADIOGRAPHIC FINDINGS 
Alveolar pattern is the main feature in thoracic radiographs in dogs with BP 
(Brady, 2004; Dear, 2014; Ford, 2009). However, prior to our study, detailed 
radiographic findings have been reported only in dogs with AP (Eom et al., 
2006; Kogan et al., 2008b; Tart et al., 2010) and in dogs with BP caused by 
Mycoplasma spp. (Jameson et al., 1995).  
As expected, an alveolar pattern was the most common finding also in our 
study, in 81% of dogs. Similiar to this, Kogan et al. (2008a) reported an 
alveolar pattern in 74% of dogs with AP. An alveolar pattern was detected less 
often, only in 44% of dogs with BP caused by Mycoplasma spp. (Jameson et 
al., 1995). These findings suggest that an alveolar pattern is less often 
encountered in BP caused by Mycoplasma infections. However, Jameson et 
al. (1995) did not detect significant differences in the radiographic pattern 
between Mycoplasma-positive and Mycoplasma-negative dogs, and 
therefore, the difference is unlikely to be explained by causative organisms. In 
our study, solely an interstitial or a bronchointerstitial pattern was discovered 
in a minority of dogs, as described previously (Jameson et al., 1995; Kogan et 
al., 2008a; Tart et al., 2010). An alveolar pattern was the most common 
finding in 75% of our Mycoplasma-positive dogs.  
Several lung lobes were most often involved in our dogs with BP (in 57% of 
dogs), and an alveolar pattern in a single lung lobe was encountered less often 
(in 23% of dogs). This differs from findings described in AP, where the 
involvement of a single lung region was most commonly described (Kogan et 
al., 2008a). Similarily as observed in cases of AP (Eom et al., 2006; Kogan et 
al., 2008b), cranioventral lung lobes were most often affected in our dogs with 
BP. Aspiration has been described to occur more often to the right lung (Eom 
et al., 2006; Kogan et al., 2008b). In our study, both right and left lungs were 
equally involved.  
In our patients, aspiration was considered a likely cause of BP in only one 
dog, in which BP developed after severe vomiting due to a gastric foreign body. 
In other dogs, aspiration etiology could not be confirmed or excluded based on 
history, clinical signs, or general examination findings, but was considered 
unlikely since none of the dogs had diseases predisposing to aspiration, recent 
vomiting, or anesthesia or clinical signs suggestive of laryngeal paralysis. 
However, laryngeal examination was performed on only a minority of dogs, 
and therefore, subclinical laryngeal dysfunction could have predisposed to 
aspiration in some dogs.  
Radiographic findings in our study were very similiar to those described in 
AP. We found alveolar density primarily in cranial and ventral lung lobes in 
dogs, where aspiration etiology was considered unlikely, suggesting that 
alveolar density in dependant lung lobes could be typical for BP regardless of 
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etiology.  It is unclear whether this is due to gravity hindering the removal of 
secretions in these areas or whether unidentified silent aspiration of small 
amounts of gastric or oral secretions plays an important role in the 
development of BP. 
A patchy alveolar pattern affecting several lung lobes was detected in 12% 
of dogs with BP in our study. A patchy alveolar pattern may not be connected 
to aspiration etiology, as it has not been described in dogs with AP (Eom et al., 
2006; Kogan et al., 2008b). 
Several human studies have addressed the need for thoracic radiographs 
when diagnosing CAP. Generally, it has been concluded that clinical signs or 
symptoms are inefficient in discriminating CAP from other lower respiratory 
diseases and confirmatory radiographic evidence is needed (Lim et al., 2009). 
Thoracic radiographs are recommended for all hospitalized patients with 
suspected CAP (Lim et al., 2009). We did not assess the need for thoracic 
radiographs in diagnosing BP, but since alveolar density typical for BP was 
discovered in most dogs at presentation and other typical clinical findings 
were not consistently present in all dogs with BP, thoracic radiographs can be 
considered important in the diagnosis of BP in dogs.  
The resolution of an alveolar lung pattern was followed during 
hospitalization and the follow-up visits. Thoracic radiographs were not 
repeated daily, and therefore, an exact time-point for the resolution could not 
be determined and the first time-point when alveolar density could no longer 
be detected was used as the time-point for resolution. Naturally, this slightly 
overestimates the time required. Alveolar infiltrates resolved relatively rapidly 
(69% of dogs had cleared alveolar infiltrates by day 10) compared with human 
studies. It has been reported that only 33% of human patients with CAP had 
clearance of radiographic infiltrates at day 7 and 62% at day 28 (Bruns et al., 
2007). In humans, it has also been shown that radiographic normalization lags 
behind clinical cure assessed by physicians (Bruns et al., 2010). Mild to 
moderate bronchial, bronchointerstitial, or interstitial pattern was still noted 
two weeks after the termination of antimicrobial treatment in the majority of 
our dogs. This finding appears to be of low importance since all of these dogs 
recovered eventually.  
Current human research has not been able to show benefits for routinely 
controlling thoracic radiographs during or after hopitalization in CAP (Lim et 
al., 2009). Especially repeating chest radiographs prior to hospital discharge 
is not recommended if treatment response is otherwise satisfactory (Lim et al., 
2009). Controlling chest radiographs after treatment has been recommended 
if there a non-satisfactory recovery or a concern of underlying lung malignancy 
(Lim et al., 2009). Our results revealed that additional information gained by 
thoracic radiographs, especially after the clearance of alveolar infiltrates, was 
minimal in dogs with otherwise satisfactory clinical recovery. Consequently, it 
could be suggested that repeating thoracic radiographs during and after 
treatment in dogs with BP e reserved for cases with poor response to treatment 
or suspected underlying lung disease. 
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6.1.3 SAMPLING METHODS AND RESPIRATORY CYTOLOGY 
BAL was a safe sampling method in our dogs with mild to moderate BP. 
Bronchoscopy allowed the selection of the sampling site and the detection of 
possible structural changes predisposing to the development of BP, such as 
bronchiectasia or TEF.  The advantage of choosing the sampling site during 
bronchoscopy resulted also in a better yield in microbiology analysis; in our 
dogs bacterial culture was more often positive and intracellular bacteria were 
more commonly seen in BALF samples than in TTW samples. This is 
concordant with Hawkins et al. (1995), who detected infectious organisms 
more often in BALF samples than in TTW samples obtained from the same 
animal.  
Cytological findings in both BALF and TTW samples were similar to the 
previously described TTW findings (Thayer and Robinson, 1984; Wingfield, 
1997); neutrophilic inflammation predominated and intracellular bacteria 
were commonly detected. Significant differences between BALF and TTW 
differential cell count were detected only in the percentage of epithelial cells. 
The higher number of epithelial cells in TTW samples is likely due to the 
sampling site of the distal trachea compared with the small airways and alveoli 
in BAL.  
In our study, TTA was chosen as a sampling method in two dogs due to a 
focal lung lesion in one dog and small size of the patient precluding TTW 
sampling in another dog. In both dogs, TTA sampling enabled the diagnosis of 
BP as neutrophilic inflammation, intracellular bacteria, and significant 
bacterial growth were detected. However, the risk of pneumothorax in TTA 
sampling has been well demonstrated (Teske et al., 1991; Wood et al., 1998), 
and also one our dogs developed a mild pneumothorax after sampling. The 
risk for the development of pneumothorax may be greater in dogs with BP due 
to fast and shallow breathing, which can cause excessive movement of the 
needle while sampling. It has been reported in humans that spontaneous 
pneumothorax can develop during CAP (Gayatridevi et al., 2015; Sayar et al., 
2004). Whether this may also occur in dogs with BP and further predispose to 
the development of pneumothorax is unknown. The risk for severe 
complications after TTA is greater in severely ill dogs (Teske et al., 1991), and 
as such a minor pneumothorax after TTA may exacerbate clinical signs in BP 
dogs that already have marked hypoxia prior to sampling.  
Sputum culture is the one of the most commonly used method in humans 
for bacterial culture in respiratory samples. The advantage in humans is the 
non-invasiveness of this sampling method, but results may be compromised 
due to inability of patients to produce good specimens, contamination with 
oropharyngeal flora, or prior antimicrobial treatment (Lim et al., 2009). 
Understandably, sputum samples are not routinely used in animals since 
volitional sputum production is not feasible. Therefore, the reliability of 
sputum samples in the assessment of microbial etiology in dogs with BP has 
not been addressed in studies. In our study, we decided to include one dog in 
which initial respiratory culture was performed from a fresh sputum sample 
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obtained after a highly productive cough. In this case, numerous neutrophils, 
intracellular bacteria, and abundant E. coli growth were detected. Later 
necropsy confirmed the diagnosis of BP and E. coli bacteremia. Sputum 
sampling is unlikely to become widely used in dogs, but in our case it was 
beneficial and enabled the isolation of the causative agent.  
6.1.4 MICROBIOLOGY RESULTS  
Pasteurella spp., E. coli, and Streptococcus spp. were the most common 
bacteria detected in our study and these results are mostly in agreement with 
previous reports (Epstein et al., 2010; Jameson et al., 1995; Proulx et al., 2014; 
Thayer and Robinson, 1984; Wingfield, 1997). Slight differences compared 
with previous reports included lack of BP caused by Staphylococcus spp. or B. 
bronchiseptica. Both could be explained by the small number of dogs included 
here. Additionally, the lack of large kennels and rehoming centers in Finland, 
typical for B. bronchiseptica infections, could have affected the results.  
A growth of a single species was detected in 69% of our dogs. Mycoplasma 
spp. were the most common second bacterial species encountered when two 
species were detected in the same sample. Previous reports described growth 
of a single species in 53% (Wingfield, 1997) and 74% (Thayer and Robinson, 
1984) of samples without specifying whether particular culture techniques for 
Mycoplasma spp. were applied. Jameson et al. (1995) reported growth of a 
single species less often (in 40% of dogs) in a study where specific 
Mycoplasma culture methods were used. In addition to culture methods, the 
results may be affected by sampling site; BAL was the main sampling method 
in our study compared with previous studies using TTW as the sampling 
method. Additionally, prior antimicrobial treatment was common in our 
patients and likely affected culture results.  
Negative bacterial cultures were encountered in 15% of dogs. This group 
comprised equal numbers of dogs with and without earlier antimicrobial 
treatment, and therefore, prior medications do not fully explain the results. In 
addition to prior antimicrobials, the sampling site of the distal trachea in TTW 
samples may have been inadequate for a representative sample in some dogs; 
in our patients undergoing bronchoscopy, purulent discharge was noted in the 
trachea in only 23% of dogs with BP. Previously, Proulx et al. (2014) reported 
negative bacterial culture findings in TTW samples in 14% of dogs with a 
clinical diagnosis of BP. Murphy et al. (1997) found a markedly higher 
proportion of negative culture findings (58%) in dogs undergoing pulmonary 
lobectomy for the treatment of pneumonia. This could be explained by patient 
characteristics; Murphy et al. (1997) included not only dogs with BP, but also 
dogs with fungal and parasitic lung infections as well as dogs with pulmonary 
neoplasia. In humans, the phenomen is well described and studies have shown 
that up to 60% of respiratory cultures are negative in CAP patients. Hence, we 
decided to include also the dogs with negative respiratory cultures if the dogs 
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fulfilled other diagnostic criteria for BP and recovered fully with solely 
antimicrobial treatment.  
Mycoplasma spp. were cultured in 27% of samples and additionally 
detected with PCR in 40% of samples.  The clinical relevance of PCR-positive 
samples is difficult to assess since the method allows the detection of very 
small quantities, and Mycoplasma spp. may be encountered also in the 
respiratory tract of healthy dogs (Randolph et al., 1993b). We detected 
Mycoplasma spp. slightly less often than previous studies reporting 
Mycoplasma spp. in 70% of dogs with BP (Jameson et al., 1995) and in 64% of 
dogs with septic lung inflammation (Randolph et al., 1993b). The role of 
Mycoplasma spp. in BP remains unclear. In our study, there were no 
significant differences in clinical variables in Mycoplasma-positive and -
negative dogs, which is in line with previous reports (Jameson et al., 1995). 
Furthermore, in our study 3/4 dogs with positive Mycoplasma culture 
received antimicrobials known to be inefficient against Mycoplasma spp. 
(amoxycillin-clavulanic acid), but recovered uneventfully. A similar finding 
has been reported by Jameson et al. (1995). In our study, Mycoplasma-
positive dogs had significantly higher total cell counts in respiratory samples 
than Mycoplasma-negative dogs. This has not been reported previously, and 
the causes as well as the clinical relevance of this finding are unknown.  
Anaerobic culture methods were applied in our study, but anaerobic 
bacteria were not detected in any of the samples. Our findings contradict the 
report of Angus et al. (1997), who detected anaerobic bacteria in 22% of 
samples. The reason for this difference can only be speculated; Angus et al. 
(1997) reported microbiological findings in 116 dogs with lower respiratory 
tract infections without specifying whether dogs with pyothorax were 
included. Since the presence of anaerobes is common in pyothorax (Walker et 
al., 2000), this could be one explanation for the discrepancy. Another possible 
factor influencing the results could be that our material comprised very few 
dogs with AP and did not include dogs with pulmonary foreign bodies; these 
patient groups could have distinct microbial findings.  
In addition to aerobic and anaerobic culture methods, an enrichment broth 
was used. The utility of an enrichment broth is uncertain. Enrichment may 
enable the detection of small amounts of causative bacteria, especially in cases 
of prior antimicrobial treatment and this is particularly beneficial because it 
allows the determination of antimicrobial susceptibility profile. However, 
since enrichment allows the detection of small amounts of bacteria, 
insignificant resident bacteria or oral contaminants may also be detected. The 
distinction between significant and insignificant bacterial growth is difficult 
since quantity of bacterial growth cannot be estimated after enrichment. A 
high number of our dogs had received antimicrobial treatment prior to 
presentation. Additionally, we were aware of a high incidence of negative 
culture results in humans with CAP, and consequently, we decided to interpret 
pure growth of a single species after enrichment as the causative agent of BP.  
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In humans, blood cultures are recommended in moderate or severe CAP 
and a positive blood culture result is considered a highly specific confirmation 
of microbial etiology (Lim et al., 2009). However, the sensitivity of blood 
cultures is rather low, at most only 25%, and prior antimicrobial treatment 
may further diminish the sensitivity (Lim et al., 2009). In canine patients, 19 
% of blood cultures were positive in septic patients (Gebhardt et al., 2009).  In 
our study, 34% of blood cultures were positive, but only 17% were consistent 
with respiratory culture findings. The finding of Staphylococcus spp. in blood 
cultures of two of our dogs was inconsistent with respiratory culture findings 
and was considered to originate from skin contamination during sampling. E. 
coli was commonly detected from blood cultures in our study and in previous 
reports (Gebhardt et al., 2009). Blood cultures were positive in severely 
affected dogs; both blood culture-positive dogs with E. coli growth died or were 
euthanized due to severe BP. However, the utility of blood cultures in dogs 
with BP is questionable. Due to low sensitivity, negative results must be 
interpreted cautiously. Positive results are likely to confirm sepsis, but 
whether blood cultures provide value beyond respiratory cultures in BP is 
unknown. Blood cultures require special equipment and are rarely available 
outside university animal hospitals. Furthermore, the size of the patient may 
limit the possibility of obtaining serial blood cultures, even if pediatric 
collection vials are used. If blood cultures are performed, it is advisable to 
obtain samples prior to the initiation of antimicrobial therapy since antibiotics 
further reduce the sensitivity (Lim et al., 2009). 
6.1.5 PROGNOSIS AND DISEASE SEVERITY 
The majority of our dogs (77%) required hospitalization and additional oxygen 
support. The number of dogs with moderate and severe BP may be affected by 
the patient material in VTHH, where a significant proportion of cases are 
referred for further investigations or hospital care from first opinion practices.  
According to our results, the prognosis for survival in dogs with BP appears 
to be good. The length of hospitalization varied greatly among dogs, but the 
majority (92%) survived to hospital discharge and recovered. This is in 
accordance with previous studies reporting 92-96% survival in dogs with BP 
(Proulx et al., 2014; Radhakrishnan et al., 2007) . Slightly lower survival rates 
(77%, 82%, and 83%) have been reported in dogs with AP (Jameson et al., 
1995; Proulx et al., 2014; Tart et al., 2010).  
Dogs with a more severe BP requiring a longer hospitalization period were 
characterized by more severe hypoxia, a more pronounced left shift in 
hematology analysis, and a more neutrophilic inflammation in respiratory 
cytology. These are not unexpected findings; the degree of hypoxia reflects the 
extent of BP (Lee and Drobatz, 2004) and the presence of band neutrophils in 
circulation indicates increased consumption as a consequence of a marked 
inflammatory process in peripheric tissues and a subsequent immature release 
of neutrophils from the bone marrow (Day, 1999). Similiar findings have been 
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reported in human studies; low PaO2 has been identified as a risk factor for 
increased mortality in humans with CAP (Basnet et al., 2015; Fine et al., 1993), 
and the absolute band neutrophil count was connected to outcome in infants 
with severe bacterial infections (Bonadio et al., 1992). Furthermore, the extent 
of neutrophilic lung inflammation in BALF has been associated with a more 
severe CAP and higher mortality in humans (Lee et al., 2015). It has been 
proposed that in addition to the organism burden severe respiratory failure 
may be due to the neutrophil-mediated inflammatory process triggering acute 
respiratory distress syndrome (Lee et al., 2015; Witko-Sarsat et al., 2000). 
Dogs with a more widespread alveolar density in thoracic radiographs were 
more severely affected with BP, as the number of affected lung lobes was 
strongly and positively correlated with the length of hospitalization in our 
dogs. This finding is consistent with Tart et al. (2010), who reported a 
significant relationship between the number of affected lung lobes and 
decreased survival in dogs with AP.  
E. coli as the causative agent was associated with a more severe BP. This is 
likely due to the endotoxins produced by E. coli affecting several body systems, 
including hemodynamics, blood clotting, and humoral immunity (Bone, 
1993). A similiar finding of increased disease severity has been reported in 
humans with CAP caused by E. coli (Marrie, 1998). Both mortalities were 
associated with severe BP caused by E. coli, and the discovery of an extended-
spectrum beta-lactamase (ESBL) strain resulted in euthanasia of one of these 
dogs. The recognition of multidrug-resistant organisms among companion 
animals has expanded within the last few years, and challenging infections 
caused by these organisms are increasingly encountered (Walther et al., 2016). 
Recently dissemination of multidrug-resistant E. coli has been reported to 
occur in a veterinary hospital (Timofte et al., 2016). ESBL organisms are a 
current problem also in human medicine, and high prevalence is reported 
especially in hospital-acquired infections and in ventilator-associated 
pneumonia (Charles et al., 2013; Behnia et al., 2014; Dabar et al., 2015).  
In humans with CAP, various severity scoring systems and predictive 
models have been developed in an attempt to help clinicians in identifying 
patients with a poor prognosis at an early stage. The most widely studied 
predictive model is the Pneumonia Severity Index (PSI). PSI is based on 20 
variables used to derive a score that estimates the risk of mortality within 30 
days (Fine et al., 1993). Factors increasing the risk of mortality were, for 
instance, high respiratory and pulse rate, elevated blood urea or glucose, low 
PaO2, and other concurrent comorbidities (Fine et al., 1993). The complexity 
of the PSI calculation limits its use in clinical practice, and a simplified scoring 
system, the CURB65 score, was developed using only patient’s degree of 
confusion, elevated blood urea concentration, increased respiratory rate, low 
blood pressure, and age of 65 years or higher as factors increasing risk of 
mortality (Lim et al., 2009). In our study, factors increasing the risk of 
mortality could not be statistically addressed due to the small number of dogs 
included and the low prevalence of mortality in the material. Factors 
 88 
connected to longer hospitalization were assessed in our study, and, except for 
low PaO2, factors known to increase the risk of mortality in men did not appear 
to affect the length of hospitalization in dogs with BP. In our dogs, blood 
glucose or urea concentrations, body temperature, age of the patient, or pulse 
rate at presentation did not correlate significantly with the length of 
hospitalization. Moreover, in dogs pulse rate is largely affected by the size of 
the animal, and therefore, is unlikely to be a useful parameter. Blood pressure 
measurements were mostly lacking, and the connection between low blood 
pressure and more severe BP was thus not evaluated. However, it appears that 
the principle in human severity scoring systems cannot be directly applied to 
dogs with BP, and larger studies are required in order to generate canine 
severity scoring systems. 
Co-infections with respiratory viruses or Mycoplasma spp. do not appear 
to result in a more severe BP; the presence of respiratory viruses or 
Mycoplasma spp. did not affect the clinical findings or the length of 
hospitalization. The effect of concurrent infections on disease severity has not 
been previously addressed in dogs with BP, but Jameson et al. (1995) reported 
similiar resolution rates for Mycoplasma-positive and -negative dogs with BP. 
The results in humans are contradictory; some studies have shown that 
humans with mixed infections with viruses and bacteria have a more severe 
course of CAP, while others have been unable to demonstrate significant 
differences (Cilloniz et al., 2012; Jennings et al., 2008; Johansson et al., 2011; 
Johnstone et al., 2008). 
6.1.6 PREDISPOSING FACTORS 
Bacterial pneumonia is generally caused by opportunistic bacteria belonging 
to the normal oropharyngeal flora, and therefore, it is important to consider 
possible predisposing factors leading to the development of BP. The etiology 
in bacterial pneumonia is likely to frequently be multifactorial, and it is often 
difficult to ascertain the impact of predisposing factors in individual dogs. 
Increased age, underlying systemic illness, poor nutrition, and 
compromised host defenses are often cited as challenging respiratory defenses 
and predisposing to the development of BP (Brady, 2004). Contrary to this, in 
our study the majority of the dogs were young or middle-aged (35% aged < 1 
year and 62% <5 years) and systemic illness was detected in only one dog. 
Simultaneous infections with CIRD viruses, mainly CPIV, were the most 
common concomitant disease process identified. The role of preceding or 
concurrent infections with CIRD viruses had not been previously evaluated in 
household dogs with BP, but in humans respiratory viruses had been shown to 
predispose to secondary bacterial lung infections (Hament et al., 1999; Joseph 
et al., 2013; Peltola and McCullers, 2004). Our results suggest that viral co-
infections can also predispose household dogs to the development of BP. Dogs 
with BP and concomittant viral infection were generally young large breed 
dogs. It is not unexpected that young dogs with possibly inadequate acquired 
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immunity against CIRD viruses may frequently contract an infection. The 
reason why large dogs with BP more often had co-infections with viruses is 
more equivocal; one hypothesis is that large dogs are more inefficient in 
clearing respiratory secretions, therefore being more at risk for the 
development of BP when infected with CIRD viruses. However, our finding of 
significantly larger dogs with viral co-infections may be also affected by the 
structure of the virus-negative group; Four virus-negative dogs with another 
predisposing factor to the development of BP were small and medium-sized.      
The prevalence of aspiration etiology in dogs with BP had not been 
evaluated previously. In our study, aspiration was considered the underlying 
factor for the development of BP in only one dog (4%). In humans with CAP, 
also a minority of patients, approximately 10%, are identified as having AP 
(Lim et al., 2009). AP refers to a situation where the infectious process in the 
lungs is a consequence to aspiration of oropharyngeal bacteria or gastic 
contents. However, with the lack of reliable markers for aspiration, the link 
between aspiration and development of BP is seldom verified and the term AP 
is commonly used in situations where a patient with risk factors for aspiration 
presents with BP. In our study, aspiration etiology was considered unlikely in 
other dogs since none of them had a history of vomiting, regurgitation, recent 
anesthesia, or signs compatible with laryngeal paralysis. However, aspiration 
may have played a role in the development of BP in some dogs, but could not 
be confirmed or denied based on available clinical data. Silent aspiration is a 
common problem in men and it may predispose to the development of 
pneumonia (Dang et al., 2015). The prevalence of silent aspiration is currently 
unknown in dogs, but it potentially may play a role as a predisposing factor in 
the development of BP also in dogs.  
Chronic bronchitis and structural changes in bronchi causing impaired 
removal of respiratory secretions were considered a predisposing cause for the 
development of BP in two dogs (8%). Both were older small breed dogs with a 
history of chronic bronchitis and an acute exacerbation of clinical signs. 
Bronchiectasis was identified in bronchoscopy in both dogs, along with 
bronchial wall irregularities and bronchomalasia. Thoracic HRCT was not 
performed in these dogs, but it would have allowed a more detailed evaluation 
of the extent of bronchiectasis. Bronchiectasis is known to increase the risk of 
bacterial infections in both men and dogs, and it could have influenced the 
development of BP in these dogs (Hill et al., 2011; Johnson et al., 2016).  
In addition to the above-mentioned, a congenital tracheoesophageal fistula 
was identified as a predisposing factor in one dog and Cushing’s disease in 
another dog with recurrent BP. An underlying disease process was not 
identified in 38% of dogs in our study. These dogs had BP caused by 
opportunistic bacteria belonging to the normal oropharyngeal flora, and 
therefore it is likely that an underlying factor or disease process, albeit 
unrevealed, has impaired the pulmonary defense mechanisms and allowed the 
development of BP. Dogs with bronchial foreign bodies were not present in 
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our material, and the absence of grass awns in our geographic location may 
have affected this.  
 
6.2 ACUTE PHASE PROTEINS IN BACTERIAL 
PNEUMONIA 
6.2.1 DIAGNOSTIC UTILITY OF ACUTE PHASE PROTEINS 
Acute phase proteins are sensitive, but non-specific inflammatory markers 
and the non-specific nature of APPs may limit their diagnostic use. However, 
serum CRP has been found to be very useful in aiding the diagnosis in humans 
with CAP, and the measurement of CRP is currently recommended by human 
guidelines (FAU et al., 1231; Lim et al., 2009; Woodhead et al., 2005). Our aim 
was to assess whether CRP could also be applied as a diagnostic biomarker in 
dogs with BP.  
We showed that dogs with BP had significantly higher serum CRP 
concentrations at presentation than healthy dogs or dogs with BTB, CB, EBP, 
CIPF, or CPE. These results suggest that serum CRP at presentation could be 
applied as an additional diagnostic biomarker in BP. However, a group of dogs 
with neoplastic lung diseases or pleural space diseases was not included in the 
study, and therefore, the applicability of serum CRP in the differentiation of 
these diseases from BP has not been evaluated. As there is a wider range of 
concentrations and the magnitude of change is more pronounced in SAA than 
in CRP, SAA might even be a better diagnostic marker than CRP in dogs with 
BP, as already suggested by a recent study comparing CRP and SAA as 
diagnostic markers of systemic inflammation (Christensen et al., 2014). Serum 
Hp and SAA were also both significantly elevated in dogs with BP relative to 
healthy dogs, but since a comparison between dogs with other respiratory 
diseases was not performed the diagnostic utility of these biomarkers remains 
obscure. At the moment, a commercial bed-side test is only available for CRP 
measurement.  
In our material, BP was diagnosed with 100% specificity when CRP was 
>100 mg/l and ruled out with 100% specificity when CRP was <20 mg/l and 
signs had lasted for more than 24 hours. Our findings are highly similar to 
those in humans with CAP, where CAP is considered likely in a patient with 
compatible clinical signs and serum CRP >100 mg/l and unlikely when CRP is 
<20 mg/l and clinical signs have lasted for more than 24 hours (Lim et al., 
2009). It is important to remember that after the initiation of inflammation 
serum CRP concentration reaches its maximum within 24 hours. Therefore, 
low concentrations in acutely presenting patients do not rule out BP. 
Nevertheless, low serum CRP in patient with clinical signs lasting >24 hours 
can be rather reliably used to rule out BP.  
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Similiar to BP, CPE can present with an acute onset of cough, tachypnea, 
or respiratory distress. In cases where thoracic radiographs or 
echocardiography are not available, serum CRP has the potential to aid 
diagnosis. Moreover, EBP occasionally presents with respiratory distress, 
alveolar density in thoracic radiographs, and lowered arterial PaO2. In these 
cases, we have found serum CRP to be especially useful; since the cytokines 
released by eosinophils do not generally trigger CRP production, eosinophilic 
lung inflammation is typically characterized by a low serum CRP contrary to 
BP.  
CRP appears to be elevated also in bacterial respiratory diseases other than 
BP; in dogs with BTB, CRP was significantly higher than in dogs with other 
lower airway diseases presenting with cough (CB, EBP) or in healthy controls. 
However, increases in CRP were mild, and although significantly higher, there 
was marked overlap between groups, reducing the diagnostic value of CRP 
measurement in the diagnosis of BTB. 
6.2.2 ACUTE PHASE PROTEINS AS FOLLOW-UP MARKERS 
Serum CRP and SAA have short half-lifes and a decrease in serum 
concentrations is expected soon after the inflammatory stimulus ceases (Ceron 
et al., 2005). Due to these properties, the utility of CRP and SAA as markers of 
treatment response was assessed in our study; CRP and SAA were followed in 
19 dogs with BP during hospitalization and the post-hospitalization recovery 
period.  
Serum CRP and SAA reflected well the recovery process and declined 
rapidly after initiation of therapy. Faster normalization was seen in dogs with 
less severe disease and a delay in the normalization of especially CRP was 
typical for dogs with more severe BP. Our findings indicate that CRP and SAA 
can be used as markers of treatment response in dogs with BP. Hp showed a 
more gradual rise and decline, and therefore, did not reflect clinical recovery 
as well as CRP and SAA. 
CRP is known to reach peak concentrations approximately 24 hours after 
onset of inflammatory stimulus, and therefore, it is not meaningful to interpret 
possible CRP decline before 24 hours after therapy initiation (Gebhardt et al., 
2009). This was seen also in our study; CRP continued to rise within the first 
24 hours in 5 dogs with an acute presentation. One of these dogs did not show 
decline in serum CRP 48 hours after treatment initiation and was later 
euthanized due to refractory BP. All other dogs showed a decline at 48 hours 
and recovered uneventfully.  
A failure to show a decline in serum CRP 48-72 hours after the initiation of 
therapy has previously been shown to be associated with a poor prognosis in 
dogs with systemic inflammatory conditions (Galezowski et al., 2010; 
Gebhardt et al., 2009; Mansfield et al., 2008). Consecutive measurements of 
CRP have been found to be useful also in humans with CAP, and the magnitude 
of CRP decline at days three and four has prognostic value (Coelho et al., 2007; 
 92 
Moreno et al., 2010). Unexpectedly, in our study the CRP ratio, describing the 
magnitude of decline after 48 or 72 hours, did not correlate with the length of 
hospitalization. This is most likely due to inherent limitations in our study 
(discussed later in the ”weaknesses of the study” section), making the 
interpretation of CRP ratio less informative. Further studies are required in 
order to assess the prognostic capacity of concecutive CRP measurements in 
dogs with BP. 
A connection has also been shown between the pattern of serum CRP and 
outcome in humans; patients with persistently high CRP (so-called non-
response) or a rise of serum CRP after initial decline (so-called biphasic 
response) during the first days of hospitalization had a poor prognosis (Coelho 
et al., 2012). In our study, one dog euthanized due to refractory BP showed a 
biphasic CPR response pattern similar to that described in connection to poor 
prognosis in humans with CAP (Coelho et al., 2012). 
6.2.3 UTILITY OF SERUM CRP MEASUREMENT IN ASSESSMENT OF 
TREATMENT LENGTH 
In BP, the severity of the infection, characteristics of the causative bacteria, 
and interactions between the pathogen and host immune system vary 
individually. Therefore, there is a need to individually customize antimicrobial 
treatment according to disease severity and response to treatment.  
Currently, published clinical studies addressing the optimal duration of 
antimicrobials in dogs with BP are not available. Antimicrobial treatment is 
recommended for 3–6 weeks, or 1–2 weeks beyond the resolution of 
radiographic changes (Dear, 2014; Ford, 2009), but current recommendations 
may overestimate the treatment length needed, especially in uncomplicated 
cases. Markedly shorter courses are used in humans with CAP; antibiotics are 
recommended for 5–10 days in cases of mild to moderate CAP (FAU et al., 
1231; Lim et al., 2009; Woodhead et al., 2011). In humans, biomarkers, such 
as procalcitonin and CRP, have proven useful in estimation of sufficient 
antimicrobial treatment length (Christ-Crain and Opal, 2010; Ehl et al., 1997; 
Jaswal et al., 2003; Long et al., 2011). 
Since it was likely that conventional recommendations in dogs with BP 
overestimate the treatment length needed, we wanted to assess whether serum 
CRP could aid in the estimation of suitable treatment length as described in 
humans (Ehl et al., 1997; Jaswal et al., 2003). However, because we did not 
have experience with how well CRP reflects the disease and recovery periods 
in BP, we decided to first monitor CRP, but treat dogs according to 
conventional recommendations. When clinical experience was gained and 
serum CRP was found to reflect the recovery process well, it was considered 
safe to stop administering antibiotics 5–7 days after CRP normalization. We 
considered ending antimicrobials at the point of CRP normalization, but it was 
thought to be too incautious, and we decided to extend the length with 5-7 days 
in order to decrease the risk of adverse effects to the patient. Later, we noticed 
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that CRP normalized rapidly almost exclusively in dogs with a less severe 
pneumonia, indicating a faster recovery in these dogs. Since decline in serum 
CRP seemed to differentiate dogs with a less severe disease, ending 
antimicrobials at the time of CRP normalization could have been sufficient.   
CRP was used to guide the duration of antimicrobial treatment in 8/17 
dogs, and it resulted in a significantly reduced treatment length compared with 
the 9 conventionally treated dogs. These results suggest that the normalization 
of serum CRP could aid in the determination of sufficient antimicrobial 
treatment length in dogs with BP. 
CRP-guided therapy did not result in relapses of BP, and therefore, the 
approach appears to be safe. However, since the incidence of relapse was low 
in both groups, it needs to be emphasized that our study did not identify an 
optimal endpoint for antimicrobial therapy, and it is possible that even shorter 
courses of treatment would be sufficient in dogs with BP. 
6.3 WEAKNESSES OF THE STUDY 
We recruited altogether 26 dogs with BP that participated in different studies 
as follows: Study I 22 dogs, Study II 19 dogs, and Study III 20 dogs. The small 
number of dogs was the most important limitation in our studies, reducing 
statistical power. The number of dogs in each group was especially small in 
Studies II and III, where the dogs were divided into two groups for further 
comparison.  
The interpretation of microbiological results was hindered by the fact that 
a cut-off value for significant bacterial growth in TTW, TTA, and sputum 
samples has not been established in dogs. We decided to apply the same cut-
off as established for BALF samples (Peeters et al., 2000), but it is possible 
that significant bacterial growth in TTW, TTA, or sputum samples may differ 
from that in BALF. However, the diagnosis of bacterial respiratory infection 
does not rely solely on the amount of bacterial growth, but also on the bacterial 
species cultured and whether cytology and other clinical findings support the 
diagnosis. Additionally, the diagnosis of BP was confirmed with post-mortem 
examination in 2/3 dogs with TTA or sputum cultures.  
The comparison between TTW and BALF results is biased by the fact that 
dogs chosen to undergo TTW sampling were generally more seriously affected 
with BP than dogs undergoing BAL. This bias was unavoidable since the most 
suitable sampling method needed to be chosen for individual dogs according 
to patient characteristics and whether general anesthesia was considered safe. 
However, notable differences were not detected between TTW and BALF 
cytology and the better yield in microbiology analysis in BALF samples is likely 
due to the sampling method rather than patient characteristics. 
The results of virus detection in Study III are affected by the patient 
characteristics and the geographical location. Because our study was 
performed in Northern Europe in household dogs with a low infection 
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pressure, it needs to be emphasized that the results may not be applicable in 
diverse situations.  
The studies assessing applicability of APPs (Studies I and II) were 
intentionally designed to exclude dogs with other concurrent diseases capable 
of increasing APP concentrations. Therefore, the results of these studies 
cannot be applied to patients with a respiratory disease and other concurrent 
infectious, inflammatory, or neoplastic diseases. Additionally, groups of dogs 
with neoplastic lung diseases or dogs with pleural space diseases were not 
included in the study, and therefore, the applicability of CRP measurement in 
the diagnosis of these diseases was not assessed.  
The interpretation of the decline in CRP during the first days of 
hospitalization is impaired by several inherent weaknesses in the study design. 
Only a small number of samples were available for CRP measurement at 72 
hours; five dogs with BP were still alive and hospitalized 72 hours after 
presentation. Another limitation concerns the method used for CRP 
measurements; the upper detection limit for the assay used was 210 mg/L, and 
measurements exceeding this were set to equal 211 mg/L. This will 
underestimate the elevation of serum CRP, as it has been shown that serum 
CRP can rise markedly above 211 mg/L in dogs with AP (Christensen et al., 
2014). These limitations have affected the results, making the interpretation 
of CRP ratio in our study less informative.  
Small sample size and lack of randomization are weaknesses in Study II, 
which assessed the applicability of serum CRP measurement in the estimation 
of antimicrobial treatment length. It would have been ideal to randomize the 
conventional and CRP-guided antimicrobial treatment groups and to stratify 
the randomization according to disease severity. 
6.4 FURTHER RESEARCH 
The etiology of BP is complex and multifactorial, and it is likely that we have 
not yet discovered all factors involved in the development of BP. It would be 
very interesting to further evaluate the role of silent aspiration in the 
development of BP as well as the role of subclinical laryngeal paralysis in 
causing silent aspiration. As microaspiration has been associated with a 
variety of chronic respiratory diseases in humans (Houghton et al., 2016), the 
role played by aspiration is intriguing, not only in dogs with BP, but also in 
dogs with CB and IPF.  
The role of bronchiectasis in dogs with BP requires further research. 
Permanent abnormal dilation of the airways contributes to the loss of normal 
mucociliary clearance and predisposes to the development of bacterial 
infections, but bronchiectasis is also a well-established post-infectious 
consequence of bacterial or viral pneumonia in humans (Hill et al., 2011). In 
dogs, bronchiectasis is also commonly encountered (Johnson et al., 2016), but 
the role of bronchiectasis as a cause or consequence of BP is largely unknown.  
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In the field of diagnostic, prognostic, and follow-up biomarkers in dogs 
with BP, there is still room for further studies. The prognostic value of repeated 
serum CRP and SAA measurements in dogs with BP remains to be investigated 
in future studies. Also it is possible that a combination of different APPs and 
various other clinical parameters would prove to be most useful as a diagnostic 
or prognostic marker. Furthermore, in addition to APPs, other novel 
biomarkers as yet uninvestigated in dogs have been shown useful in humans 
as diagnostic and follow-up markers in CAP. Procalcitonin has been widely 
studied in humans with CAP (Christ-Crain et al., 2006; Long et al., 2011), but 
due to lack of reliable canine laboratory assays (Floras et al., 2014) the utility 
of procalcitonin has not yet been evaluated in dogs. Amino terminal pro-C-
type natriuretic peptide (NT-pro-CNP) has also been suggested but not yet 
evaluated as a potential biomarker in septic respiratory infections (Smith et 
al., 2015). 
Therapy of BP is largely based on clinical experience and extrapolations 
from human studies, and clinical studies have not yet addressed therapeutic 
aspects of BP in dogs. Currently, there is clinical data available on the most 
common pathogens and antimicrobial susceptibility in BP, enabling general 
recommendations for empirical antimicrobial treatment. Our study addressed 
the antimicrobial treatment length and may serve as a pilot study in this field, 
but larger randomized studies are needed to investigate the true applicability 
of serum APP measurements in guiding the length of antimicrobial treatment.  
Critical illness-related corticosteroid insufficiency has been reported to 
occur in both human and canine patients with severe sepsis (Creedon, 2015; 
Marik et al., 2008; Martin, 2011). Additionally, it has been shown in humans 
with CAP that adjunctive corticotherapy in the management of CAP in 
hospitalized patients reduces the length of hospital stay and the number of 
severe complications (Marti et al., 2015) The effect of adjunctive corticosteroid 
treatment on mortality in patients with CAP remains uncertain (Marti et al., 
2015). It would be of interest to investigate the incidence of critical illness-
related corticosteroid insufficiency in dogs with BP as well the possible 
therapeutic applications of adjunctive corticosteroid treatment in dogs with 
severe BP.  
A breed-specific rhinitis-bronchopneumonia has been reported in Irish 
wolfhounds, but the etiology of this disease is not fully known (Clercx et al., 
2003). An increased incidence of AP has been also suggested in this breed 
(Greenwell and Brain, 2014). The background for this apparent breed 
predisposition warrants clarification.  
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7 CONCLUSIONS 
1. Serum CRP, SAA, and Hp concentrations were significantly elevated at 
presentation in dogs with BP. CRP and SAA declined rapidly after 
initiation of therapy and reflected well the recovery process, indicating 
potential use as markers of treatment response in dogs with BP. 
 
2. Serum CRP is significantly increased in dogs with BP relative to healthy 
dogs and dogs with BTB, CB, EBP, CIPF, and CPE, and therefore, serum 
CRP can be used as an additional diagnostic biomarker in BP. 
Furthermore, increases in serum CRP are not typical in dogs with CB, 
EBP, or CIPF; if encountered in these patients, a secondary infectious 
process may be suspected.  
 
3. When normalization of serum CRP was used to guide antimicrobial 
treatment length, treatment length was significantly reduced without 
increasing the number of relapses. According to these results, 
normalization of serum CRP may be applied to guide the length of 
antimicrobial therapy in dogs with BP. 
 
4. Respiratory viruses, primarily CPIV, were found frequently in lower 
respiratory tract samples of dogs with BP. This indicates that viruses 
may play an important role in the etiology of BP. Viral co-infections did 
not affect disease severity or clinical variables in dogs with BP. 
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